(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 February 2010 (04.02.2010)

PCT

(10) International Publication Number
WO 2010/014794 A1

(51) **International Patent Classification**:
A01N 43/30 (2006.01)

(21) **International Application Number**:
PCT/US2009/052225

(22) **International Filing Date**:
30 July 2009 (30.07.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/084,770 30 July 2008 (30.07.2008) US

(71) **Applicant** *(for all designated States except US)*: **ONCOTHERAPY SCIENCE, INC.** [JP/JP]; 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa 2130012 (JP).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **OHTANI, Mitsuaki** [JP/JP]; c/o Oncotherapy Science, Inc., 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa 2130012 (JP). **MATSUO, Yo** [JP/JP]; c/o Oncotherapy Science, Inc., 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa 2130012 (JP). **LI, Yingfu** [CN/US]; 38 Cambridge Avenue, Clifton Park, New York 12065 (US). **WALKER, Joel, R.** [US/US]; 38 Terry Avenue, Schenectady, New York 12303 (US). **JENKINS, David, M.** [US/US]; 96 Fonda Road, Cohoes, New York 12047 (US). **AHMED, Feryan** [PK/US]; 23 Belle Avenue, Latham, New York 12110 (US). **OHSAWA, Ryuji** [JP/JP]; c/o Oncotherapy Science, Inc., 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa 2130012 (JP). **HISADA, Shoji** [JP/JP]; c/o Oncotherapy Science, Inc., 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa 2130012 (JP).

(74) **Agents**: **TRIMBLE, Alexander, R.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, California 94111-3834 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2010/014794 A1

(54) **Title**: BENZOIMIDAZOLE DERIVATIVES AND GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING THE SAME

(57) **Abstract**: Benzoimidazole Derivatives are provided. The compounds of the present invention are useful for Glycogen Synthase Kinase-3 Beta Inhibitors.

Benzoimidazole Derivatives and Glycogen Synthase Kinase-3 Beta Inhibitors Containing the Same

Priority

The present application claims the benefit of U.S. Provisional Application No. 61/084,770, filed on July 30, 2008, the entire contents of which are incorporated by reference herein.

Technical Field

The present invention relates to a compound for inhibiting glycogen synthase kinase-3 (GSK3) activity, a method for the preparation thereof, and a pharmaceutical composition containing the compound as an active ingredient.

Background Art

Glycogen synthase kinase-3 (GSK3) is a proline-directed serine-threonine kinase that was initially identified as a protein which inactivates glycogen synthase through phosphorylation. Two isoforms have been identified, alpha (GSK3alpha) and beta (GSK3beta), which show a high degree of amino acid homology to each other. Previous studies have reported that the GSK3beta is involved in energy metabolism, neural cell development, and body pattern formation (Plyte SE, et al., Biochim. Biophys. Acta, 1114:147-162, 1992).

Neurodegenerative naturopathies, including Alzheimer disease, are characterized by abnormal hyperphosphorylation of the microtubule-associated protein tau at proline-directed serine/threonine phosphorylation sites (Lee VM, et al., *Annu. Rev. Neurosci.* **24**: 1121-1159, 2001.). GSK3beta has been identified as a prime candidate mediating aberrant tau phosphorylation at disease-associated sites (Hanger DP, et al., *Neurosci. Lett.* **147**: 58-62, 1992., Ishiguro K, et al., *J. Biol. Chem.* **267**: 10897-10901, 1992., Mandelkow EM, et al., *FEBS Lett.* **314**: 315-321, 1992. and Paudel HK, et al., *J. Biol. Chem.* **268**: 23512-23518, 1993.). Hence, GSK3beta is a promising target for therapeutic intervention in neurodegenerative tauopathies including Alzheimer disease.

Lithium carbonate, lithium citrate and lithium chloride are commonly used for the treatment of various disorders like mania, depression and migraine, and also used as an "augmenting" agent to increase the benefits of other standard drugs used for unipolar depression. Lithium is a GSK3beta inhibitor, and therefore, GSK3beta inhibition is a promising target for the treatment of various such disorders.

There have been reports that the activity of GSK3 in obese diabetic mice is about twice as high as that in control (Eldar-Finkelman H, et al., Diabetes, 48:1662-1666, 1999), and the activity and expression of GSK3 in patients with type 2 diabetes is significantly higher relatively to that in normal persons (Nikoulina SE, et al., Diabetes, 49:263-271, 2000). Therefore, GSK3 inhibitors are available for treatment of type 2 diabetes by reducing the activity of glucose synthase.

Taken together, GSK3beta inhibitors can be used for a broad spectrum of diseases such as Alzheimer disease, mania, depression, migraine and type 2 diabetes and there is a strong need to develop such inhibitors for the treatment and/or prevention of GSK3beta dependent diseases.

The present inventors have found that benzoimidazole derivatives can selectively inhibit the activity of GSK3beta and are therefore useful for treatment and/or prevention of GSK3beta dependent diseases.

Summary of Invention

Accordingly, it is an object of the present invention to provide GSK3beta inhibitors having high inhibitory activity against GSK3beta.

It is another object of the present invention to provide a method for preparing such inhibitors.

It is a further object of the present invention to provide a pharmaceutical composition including said compounds, pharmaceutically acceptable salts, hydrates, solvates, and isomers thereof.

In accordance with one aspect of the present invention, there is provided a compound of formula (I), and a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof:



(I)

wherein,

ring A is (II), (III), (IV) (V), or (VI)



(II) (III) (IV) (V) or (VI)

wherein

X is halogen or hydroxyl;

Y is hydrogen, phenyl, thiophen-2-yl, furan-2-yl, cyclopropyl, or cyclopentyl;

Z is a 5-10 membered heterocycle substituted carbonylamino; and

Ring A is substituted by $-L^1-(CH_2)_a-L^2-M$ at position *;

L^1 is -CONH-, -NHCO-, or a single bond;

L^2 is selected from the group consisting of -NH-, -O-, $-CH(COOR^1)-$, $-CH(CH_2OH)-$, -CH=CH- and a single bond, wherein R^1 is hydrogen or C_1-C_6 alkyl;

M is selected from the group consisting of hydroxyl, carboxyl, amide, C_1-C_6 alkyl, C_1-C_6 alkylcarbonyl, C_6-C_{14} aryl, C_6-C_{14} aryl C_1-C_6 alkyl, C_6-C_{14} arylcarbonyl, C_6-C_{14} arylsulfonyl, 5-14 membered saturated, unsaturated or aromatic heterocyclic group, 5-14 membered unsaturated or aromatic heterocyclic group substituted C_1-C_6 alkyl, 5-14 membered unsaturated or aromatic heterocyclic group substituted sulfonyl or $-NR^2R^3$;

wherein R^2 and R^3 are independently C_1-C_6 alkyl;

the C_1-C_6 alkyl, C_1-C_6 alkylcarbonyl, C_6-C_{14} aryl, C_6-C_{14} aryl C_1-C_6 alkyl, C_6-C_{14} arylcarbonyl, C_6-C_{14} arylsulfonyl, 5-14 membered unsaturated or aromatic heterocyclic group, 5-14 membered unsaturated or aromatic heterocyclic group substituted C_1-C_6alkyl, and 5-14 membered unsaturated or aromatic heterocyclic group substituted sulfonyl are optionally substituted by 1-3 substituent(s) each independently selected from group A;

wherein group A consists of hydroxyl, oxo, nitro, amino, amide, halogen, sulfamoyl, trifluolomethyl, p-toluenesulfonylamino, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkylcarbonylamino, and C_1-C_6 alkylsulfonylamino; and

a is 0-5 integer.

Description of Embodiments

Definitions

In this invention, "alkyl" refers to a straight chain or a branched chain hydrocarbon group which does not contain any hetero atoms or unsaturated carbon-carbon bonds. "C_1-C_6 alkyl" refers to an alkyl group which has 1-6 carbon atoms. "C_1-C_4 alkyl" refers to an alkyl group which has 1-4 carbon atoms.

Examples of "C_1-C_6 alkyl" include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 1-butyl, 2-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 2,2-dimethyl-1-propyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2-methy-3-pentyl, 3-methyl-3-pentyl, 2,3-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2,2-dimethyl-1-butyl, 2-ethyl-1-butyl, 3,3-dimethyl-2-butyl, and 2,3-dimethyl-2-butyl.

In the present invention, "alkoxy" refers to a group represented by -OR, wherein R is alkyl.

"C_1-C_6 alkoxy" refers to an alkoxy group which has 1-6 carbon atoms. "C_1-C_4 alkoxy" refers to an alkoxy group which has 1-4 carbon atoms.

Examples of "C_1-C_6 alkoxy" include, but are not limited to, methoxy, ethoxy, 1-propyloxy, 2-propyloxy, 2-methyl-1-propyloxy, 2-methyl-2-propyloxy, and 1-butyloxy, and 2- butyloxy.

In the present invention, "carbonyl" refers to a group represented by -(C=O)-.

In this invention, "C_1-C_6 alkylcarbonyl" refers to a carbonyl group bound to the C_1-C_6 alkyl. "C_1-C_4 alkylcarbonyl" refers to a carbonyl group bound to theC_1-C_4 alkyl.

Examples of "C_1-C_6 alkylcarbonyl" include, but are not limited to, methylcarbonyl, ethylcarbonyl, 1-propylcarbonyl, 2-propylcarbonyl, n-butylcarbonyl, s-butylcarbonyl, *t*-butylcarbonyl, and 2-ethylbutylcarbyl.

In this invention, "amino" refers to a group represented by -NH_2 in which the hydrogens are optionally replaced by a substituent.

In the present invention, "C_1-C_6 alkylcarbonylamino" refers to an amino group bound to the C_1-C_6 alkylcarbonyl. "C_1-C_4 alkylcarbonylamino" refers to an amino group bound to the C_1-C_4 alkylcarbonyl.

Examples of "C_1-C_6 alkylcarbonylamino" include, but are not limited to, methylcarbonylamino, ethylcarbonylamino, 1-propylcarbonylamino, 2-propylcarbonylamino, n-butylcarbonylamino, s-butylcarbonylamino, *t*-butylcarbonylamino, and 2-ethylbutylcarbonylamino.

In this invention, "sulfonyl" is a group represented by -SO_2-.

In this invention, "C_1-C_6 alkylsulfonyl" refers to a sulfonyl group bound to the C_1-C_6 alkyl. "C_1-C_4 alkylsulfonyl" refers to a sulfonyl group bound to the C_1-C_4 alkyl.

Examples of "C_1-C_6 alkylsulfonyl" include, but are not limited to, methylsulfonyl, ethylsulfonyl, 1-propylsulfonyl, 2-propylsulfonyl, n-butylsulfonyl, s-butylsulfonyl, t-butylsulfonyl, and 2-ethylbutylsulfonyl.

In the present invention, "C_1-C_6 alkylsulfonylamino" refers to an amino group bound to the"C_1-C_6 alkylsulfonyl". "C_1-C_4 alkylsulfonylamino" refers to an amino group bound to the"C_1-C_4 alkylsulfonyl".

Examples of "C_1-C_6 alkylsulfonylamino" include, but are not limited to, methylsulfonylamino, ethylsulfonylamino, 1-propylsulfonylamino, 2-propylsulfonylamino, n-butylsulfonylamino, s-butylsulfonylamino, t-butylsulfonylamino, and 2-ethylbutylsulfonylamino.

In the present invention, "aryl" refers to an aromatic carbon ring system. "C_6-C_{14} aryl" refers to a 6-14 membered aryl ring. "C_6-C_{10} aryl" refers to a 6-10 membered aryl ring.

Examples of "C_6-C_{14} aryl" include, but are not limited to, phenyl, naphthyl, and anthryl.

In the invention, "C_6-C_{14} aryl C_1-C_6 alkyl" refers to the"C_1-C_6 alkyl" in which a hydrogen atom is substituted by the"C_6-C_{14} aryl". "C_6-C_{10} arylC_1-C_4 alkyl" refers to the"C_1-C_4 alkyl" in which a hydrogen atom is substituted by the"C_6-C_{10} aryl".

Examples of "C_6-C_{14}arylC_1-C_6alkyl" include, but are not limited to, benzyl, phenethyl, and anthrylmethyl.

In the present invention, "C_6-C_{14} arylcarbonyl" refers to a carbonyl group bound to the"C_6-C_{14} aryl". "C_6-C_{10} arylcarbonyl" refers to a carbonyl group bound to the"C_6-C_{10} aryl".

Examples of "C_6-C_{14} arylcarbonyl" include, but are not limited to, phenylcarbonyl, naphthylcarbonyl, and anthrylcarbonyl.

In this invention, "C_6-C_{14} arylsulfonyl" refers to a sulfonyl group bound to the"C_6-C_{14} aryl". "C_6-C_{10} arylsulfonyl" refers to a sulfonyl group bound to the"C_6-C_{10} aryl".

Examples of "C_6-C_{14}arylsulfonyl" include, but are not limited to, phenylsulfonyl, naphthylsulfonyl, and anthrylsulfonyl.

In the present invention, "an unsaturated or aromatic heterocyclic group" refers to an unsaturated or aromatic heterocyclic group having one or more hetero atom in the ring system. "5-14 membered unsaturated or aromatic heterocyclic group" refers to an unsaturated or aromatic heterocyclic group in which the ring consists of 5-14 atoms. "5-10 membered unsaturated or aromatic heterocyclic group" refers to a unsaturated or aromatic heterocyclic group in which the ring consists of 5-10 atoms.

Examples of "5-14 membered unsaturated or aromatic heterocyclic group" include, but are not limited to, imidazolyl, pyrrolyl, pyridyl, thienyl, furyl, thiazolyl, pyrazolyl, pyrazolinyl, oxazolyl, isoxazolyl and indolyl.

In this invention, "5-14 membered unsaturated or aromatic heterocyclic group substituted C_1-C_6 alkyl" refers to the "C_1-C_6 alkyl" in which a hydrogen atom is substituted by the"5-14 membered unsaturated or aromatic heterocyclic group". "5-10 membered unsaturated or aromatic heterocyclic group substituted C_1-C_4 alkyl" refers to the "C_1-C_4 alkyl" in which a hydrogen atom is substituted by the"5-10 membered unsaturated or aromatic heterocyclic group".

Examples of "5-14 membered unsaturated or aromatic heterocyclic group substituted C_1-C_6 alkyl" include, but are not limited to, imidazolylmethyl, pyrrolylmethyl, pyridylmethyl, thienylmethyl, furylmethyl, thiazolylmethyl, pyrazolylmethyl, pyrazolinylmethyl, oxazolylmethyl, isoxazolylmethyl, and indolylmethyl.

In this invention, "5-14 membered unsaturated or aromatic heterocyclic group substituted sulfonyl" refers to a sulfonyl group bound to the 5-14 membered unsaturated or aromatic heterocyclic group". "5-10 membered unsaturated or aromatic heterocyclic group substituted sulfonyl" refers to a sulfonyl group bound to "5-10 membered unsaturated or aromatic heterocyclic group".

Examples of "5-14 membered unsaturated or aromatic heterocyclic group substituted sulfonyl" include, but are not limited to, imidazolylsulfonyl, pyrrolylsulfonyl, pyridylsulfonyl, thienylsulfonyl, furylsulfonyl, thiazolylsulfonyl, pyrazolylsulfonyl, pyrazolinylsulfonyl, oxazolylsulfonyl, isoxazolylsulfonyl, and indolylsulfonyl.

In this invention, "5-10 membered unsaturated or aromatic heterocyclic group substituted carbonylamino" refers to an amino group bound to a carbonyl group bound to the "5-10 membered unsaturated or aromatic heterocyclic group".

Examples of "5-10 membered unsaturated or aromatic heterocyclic group substituted carbonylamino" include, but are not limited to, imidazolylcarbonylamino, pyrrolylcarbonylamino, pyridylcarbonylamino, thienylcarbonylamino, furylcarbonylamino, thiazolylcarbonylamino, pyrazolylcarbonylamino, pyrazolinylcarbonylamino, oxazolylcarbonylamino, isoxazolylcarbonylamino, and indolylcarbonylamino.

In the present invention, "a saturated heterocyclic group" refers to a saturated heterocyclic group having one or more hetero atom in the ring system. "5-14 membered saturated heterocyclic group" refers to a saturated heterocyclic group in which the ring consists of 5-14 atoms. "5-10 membered saturated heterocyclic group" refers to a saturated heterocyclic group in which the ring consists of 5-10 atoms.

Examples of "5-14 membered saturated heterocyclic group" include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl.

A salt is defined as the product formed from the neutralisation reaction of acids and bases. Salts are ionic compounds composed of cations (positively charged ions) and anions (negative ions) so that the product is electrically neutral. These component ions can be inorganic as well as organic.
Hydrate is a term used in inorganic chemistry and organic chemistry to indicate that a substance contains water. Solvate refers to a molecule in a solution complexed by solvent molecules.
Isomers are compounds with the same molecular formula but different structural formulae.
More specifically, isomer includes geometric isomer, optical isomer, stereoisomer, tautomer of the compound, and mixtures thereof.

The present invention provides a compound represented by formula (I):



(I)

Among the compounds of formula (I) of the present invention, the preferred are those wherein:

A is (II),



(II)

wherein

X is halogen or hydroxyl;

Y is phenyl, thiophen-2-yl, furan-2-yl, cyclopropyl, or cyclopentyl;

Ring (II) is substituted by $-L^1-(CH_2)_a-L^2-M$ at position *;

L^1 is -CONH- or -NHCO-;

L^2 is selected from the group consisting of -NH-, -O-, -CH(COOR^1)-, -CH(CH_2OH)-, and a single bond, wherein R^1 is hydrogen or C_1-C_6 alkyl;

M is selected from the group consisting of hydroxyl, carboxyl, amide, C_1-C_6 alkyl, C_1-C_6 alkylcarbonyl, C_6-C_{14} aryl, C_6-C_{14} aryl C_1-C_6 alkyl, C_6-C_{14} arylcarbonyl, C_6-C_{14} arylsulfonyl, 5-14 membered saturated, unsaturated or aromatic heterocyclic group, 5-14 membered unsaturated or aromatic heterocyclic group substituted C_1-C_6alkyl, 5-14 membered unsaturated or aromatic heterocyclic group substituted sulfonyl or -NR^2R^3;

wherein R^2 and R^3 are independently C_1-C_6 alkyl;

the C_1-C_6 alkyl, C_1-C_6 alkylcarbonyl, C_6-C_{14} aryl, C_6-C_{14} aryl C_1-C_6 alkyl, C_6-C_{14} arylcarbonyl, C_6-C_{14} arylsulfonyl, 5-14 membered unsaturated or aromatic heterocyclic group, 5-14 membered unsaturated or aromatic heterocyclic group substituted by C_1-C_6 alkyl, and 5-14 membered unsaturated or aromatic heterocyclic group substituted sulfonyl are optionally substituted by 1-3 substituent(s) each independently selected from group A;

wherein group A consists of hydroxyl, oxo, nitro, amino, amide, halogen, sulfamoyl, trifluolomethyl, p-toluenesulfonylamino, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkylcarbonylamino, and C_1-C_6 alkylsulfonylamino; and

a is an integer from 0-5.

In a preferred embodiment, the present invention provides compounds represented by following formula (I-II) or a salt, hydrate, solvate, or isomer thereof:



(I-II)

wherein

L^1 is -CONH-;

L^2 is a single bond;

M is C_6-C_{10} aryl or 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S, which are optionally substituted by 1 or 2 substituent(s) each independently selected from the group A; and

X, Y, and a are defined as in above embodiment represented by formula (I).

In this embodiment, M is selected from the group consisting of phenyl, imidazole-1-yl, imdazole-2-yl, imidazole-5-yl, thiophen-2-yl, pyrole-2-yl, 1,3-thiazole-2-yl, 2-pyrazoline-4-yl, and isoxazole-4-yl, which are optionally substituted by 1-2 substituent(s) each independently selected from following group B, and Y is selected from the group consisting of thiophen-2-yl, furan-2-yl, phenyl, cyclopropyl, and cyclopentyl.

Group B consists of fluoro, hydroxyl, oxo, amino, methyl, methoxy, and sulfamoyl.

Preferred compounds include those selected from the group consisting of: Example Nos. 8, 9, 10, 20, 21, 22, 23, 35, 37, 44, 45, 57, 62, 76, 77, 78, 79, 80, 84, 85, 86, 90, 91, 92, 93, 94, 95, 96, 101 and 102 listed in Table 1 below; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compounds.

Table 1

Example No.	structure	compound
8		7-Hydroxy-N-(4-sulfamoylbenzyl)-2-(thiophen-2-yl)-1H-benzo [d]imidazole-4-carboxamide
9		N-(2,4-Difluorobenzyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo [d]imidazole-4-carboxamide
10		7-Hydroxy-N-(thiazol-2-yl)-2-(thiophen-2-yl)-1H-benzo[d]imid azole-4-carboxamide
20		7-Hydroxy-2-(thiophen-2-yl)-N-[2-(thiophen-2-yl)ethyl]-1H-be nzo[d]imidazole-4-carboxamide
21		7-Hydroxy-N-(4-sulfamoylphenethyl)-2-(thiophen-2-yl)-1H-be nzo[d]imidazole-4-carboxamide
22		7-Hydroxy-N-(3-methoxyphenethyl)-2-(thiophen-2-yl)-1H-ben zo[d]imidazole-4-carboxamide
23		7-hydroxy-N-(3-methoxyphenethyl)-2-(thiophen-2-yl)-1H-benz o[d]imidazole-4-carboxamide

35		7-Hydroxy-N-[2-(1-methyl-1H-imidazol-5-yl)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
37		N-(3,4-Dihydroxybenzyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
44		N-(4-Fluorophenethyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
45		7-Hydroxy-N-(4-hydroxyphenethyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
57		N-3-(1H-Imidazol-2-yl)propyl)-]7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
62		N-[2-(1H-Imidazol-2-yl)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
76		N-[3-(1H-Imidazol-1-yl)propyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
90		N-[2-(1H-Imidazol-5-yl)ethyl]-7-fluoro-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide

77		2-(Furan-2-yl)-7-hydroxy-N-phenethyl-1H-benzo[d]imidazole-4-carboxamide
78		2-(Furan-2-yl)-7-hydroxy-N-phenyl-1H-benzo[d]imidazole-4-carboxamide
79		7-Hydroxy-N-[3-(5-oxo-4,5-dihydro-1H-pyrazol-4-yl)propyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
80		N-(3,4-Dihydroxyphenethyl)-2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxamide
84		2-(Furan-2-yl)-7-hydroxy-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1H-benzo[d]imidazole-4-carboxamide
85		N-(2-(3,5-dimethylisoxazol-4-yl)ethyl)-2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxamide
86		2-(Furan-2-yl)-7-hydroxy-N-(thiazol-2-yl)-1H-benzo[d]imidazole-4-carboxamide
92		4-Hydroxy-N-(4-hydroxyphenethyl)-2-phenyl-1H-benzo[d]imidazole-7-carboxamide

93		N-(4-Aminophenethyl)-4-hydroxy-2-phenyl-1H-benzo[d]imidazole-7-carboxamide
94		4-Hydroxy-N-phenethyl-2-phenyl-1H-benzo[d]imidazole-7-carboxamide
91		2-Cyclopropyl-N-(4-hydroxyphenyl)-4-methoxy-1H-benzo[d]imidazole-7-carboxamide
101		2-Cyclopropyl-4-hydroxy-N-(4-sulfamoylphenethyl)-1H-benzo[d]imidazole-7-carboxamide
102		2-Cyclopropyl-N-(4-fluorophenethyl)-4-hydroxy-1H-benzo[d]imidazole-7-carboxamide
95		2-Cyclopentyl-4-hydroxy-N-(4-hydroxyphenethyl)-1H-benzo[d]imidazole-7-carboxamide
96		N-(4-Aminophenethyl)-2-cyclopentyl-4-hydroxy-1H-benzo[d]imidazole-7-carboxamide

In another preferred embodiment, the present invention provides a compound represented by following formula (I- II) or a salt, hydrate, solvate, or isomer thereof :



(I-II)

wherein

L^1 is -CONH-;

L^2 is -NH-;

M is C_1-C_4 alkyl, C_1-C_4 alkylcarbonyl, C_6-C_{10} arylcarbonyl, C_6-C_{10} arylsulfonyl, 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S or sulfonyl substituted by 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S, which are optionally substituted by 1 or 2 substituent(s) each independently selected form the group A; and

X, Y, and a are defined as in the above embodiment represented by formula (I).

In this embodiment, M is selected from the group consisting of ethyl, isopropyl, methylcarbonyl, pyridine-2-yl, phenylcarbonyl, phenylsulfonyl, and 4-pyridilsulfonyl, which are optionally substituted by 1-2 substituent(s) each independently selected from following group C, and Y is selected from the group consisting of thiophen-2-yl and furan-2-yl.

Group C consists of chloro, hydroxyl, methyl, methylcarbonylamino, methylsulfonylamino, and p-toluenesulfonylamino.

In one preferred embodiment, the present invention provides the compound selected from the group consisting of: Example Nos. 11, 12, 38, 39, 40, 41, 42, 43, 69, 70 and 89 listed in Table 2 below, and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compounds.

Table 2

Example No.	structure	Compound
11		7-Hydroxy-N-[2-(pyridin-2-ylamino)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
12		7-Hydroxy-N-[3-(2-hydroxyethylamino)propyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide

38		7-Hydroxy-N-[2-(phenylsulfonamido)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
39		N-[2-(4-Chlorophenylsulfonamido)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
40		7-Hydroxy-N-[2-(pyridine-4-sulfonamido)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
41		7-Hydroxy-N-[2-(4-methylbenzamido)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
42		N-(2-Acetamidoethyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
43		N-[3-(Isopropylamino)propyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
69		7-Hydroxy-N-{2-[5-(methylsulfonamido)pyridin-2-ylamino]ethyl}-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
70		N-[2-(5-Acetamidopyridin-2-ylamino)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide

89		2-(Furan-2-yl)-7-hydroxy-N-{2-[5-(4-methylphenylsulfonamido)pyridin-2-ylamino]ethyl}-1H-benzo[d]imidazole-4-carboxamide

In another preferred embodiment, the present invention provides a compound represented by following formula (I-II) or a salt thereof:



(I-II)

wherein

L^1 is -CONH-;

L^2 is -CH($COOR^1$)-, wherein R^1 is hydrogen or C_1-C_4 alkyl;

M is C_1-C_4 alkyl, C_6-C_{10} aryl C_1-C_4 alkyl or C_1-C_4 alkyl substituted by 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S , which are optionally substituted by 1 or 2 substituent(s) each independently selected from the group A; and

X, Y, and a are defined as in the above embodiment represented by formula (I).

In this embodiment, M is selected from the group consisting of methyl, phenylmethyl, indole-3-ylmethyl, and imidazole-4-ylmethyl, which are optionally substituted by 1-2 hydroxyl, and Y is thiophen-2-yl.

In one preferred embodiment, the present invention provides the compound selected from the group consisting of: Example Nos. 13, 14, 15, 16, 71 and 72 listed in Table 3 below, and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compounds.

Table 3

Example No.	structure	compound
13		(S)-Methyl 2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(1H-imidazol-5-yl)propanoate
14		(S)-Methyl 2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(1H-indol-3-yl)propanoate

15		Methyl 3-Hydroxy-2-[7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]propanoate
16		Methyl 2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(4-hydroxyphenyl)propanoate
71		(S)-2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(1H-imidazol-5-yl)propanoic Acid
72		(S)-2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(1H-indol-3-yl)propanoic Acid

In another preferred embodiment, the present invention provides a compound represented by following formula (I- II) or a salt, hydrate, solvate, or isomer thereof:



(I-II)

wherein

L^1 is -CONH-;

L^2 is - O-;

M is C_6-C_{10} aryl or 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S, which are optionally substituted by 1 or 2 substituent(s) each independently selected from the group A;

X, Y, and a are defined in the above embodiment represented by formula (I).

In this embodiment, M is phenyl or pyridine-2-yl, which is optionally substituted by 1 or 2 substituent(s) each independently selected from following group D, and Y preferably consists of thiophen-2-yl.

Group D consists of amide, nitro, trifluoromethyl, and p-toluenesulfonylamino.

In one preferred embodiment, the present invention provides the compound selected from the group consisting of: Example Nos. 49, 50, 73 and 74 listed in Table 4 below, and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compounds.

Table 4

Example No.	structure	compound
49		N-[2-(5-Carbamoylpyridin-2-yloxy)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
50		7-Hydroxy-2-(thiophen-2-yl)-N-[2-(5-(trifluoromethyl)pyridine-2-yloxy)ethyl]-1H-benzo[d]imidazole-4-carboxamide
73		7-Hydroxy-N-[2-(4-nitrophenoxy)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
74		7-Hydroxy-N-{2-[4-(4-methylphenylsulfonamido)phenoxy]ethyl}-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide

In another preferred embodiment, the present invention provides the compounds represented by following formula (I-II) or a salt, hydrate, solvate, or isomer thereof:



(I-II)

wherein

L^1 is -CONH-;

L^2 is - $CH(CH_2OH)$-;

M is selected from the group consisting of hydroxyl, C_1-C_4 alkyl, C_6-C_{10} aryl C_1-C_4 alkyl, and C_1-C_4 alkyl substituted by 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S, the C_1-C_4 alkyl, C_6-C_{10} aryl C_1-C_4 alkyl, and 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) are optionally substituted by 1 or 2 substituent(s) each independently selected from the group A; and

X, Y, and a are defined as in the above embodiment represented by formula (I).

In this embodiment, M is preferably hydroxyl, phenylmethyl, t-butyl, or imidazole-5-ylmethyl, and Y is selected from the group consisting of thiophen-2-y and cyclopropyl.

In one preferred embodiment, the present invention provides the compound selected from the group consisting of: Example Nos. 17, 18, 19 and 97 listed in Table 5 below, and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compounds.

Table 5

Example No.	structure	compound
17		(R)-7-Hydroxy-N-[1-hydroxy-3-(1H-imidazol-4-yl)propan-2-yl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
18		(S)-7-Hydroxy-N-(1-hydroxy-3,3-dimethylbutan-2-yl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
19		(S)-7-Hydroxy-N-(1-hydroxy-3-phenylpropan-2-yl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
97		2-Cyclopropyl-N-(2,3-dihydroxypropyl)-4-hydroxy-1H-benzo[d]imidazole-7-carboxamide

In another preferred embodiment, the present invention provides a compound represented by following formula (I-II) or a salt, hydrate, solvate, or isomer thereof :



(I-II)

wherein

L^1 is -CONH-;

L^2 is a single bond;

M is $-NR^2R^3$;

wherein R^2 and R^3 are independently C_1-C_4 alkyl optionally substituted by 1 or 2 substituent(s) each independently selected from the group A; and

X, Y, and a are defined in the above embodiment represented by formula (I).

In this embodiment, Y is selected from the group consisting of thiophen-2-yl and cyclopropyl.

In one preferred embodiment, the present invention provides the compound selected from the group consisting of: Example Nos. 36 and 98 listed in Table 6 below, and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compounds.

Table 6

Example No.	structure	compound
36		N-[2-(dimethylamino)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide
98		2-Cyclopropyl-N-(2-(dimethylamino)ethyl)-4-hydroxy-1H-benzo[d]imidazole-7-carboxamide

In another preferred embodiment, the present invention provides a compound represented by following formula (I-II) or a salt, hydrate, solvate, or isomer thereof:



(I-II)

wherein

L^1 is -NHCO-;

L^2 is -NH-, -CH=CH- or a single bond;

M is C_6-C_{10} aryl or 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S, which are optionally substituted by 1 or 2 substituent(s) each independently selected from the group A; and

X, Y, and a are defined as in the above embodiment represented by formula (I).

In this embodiment, M is preferably phenyl optionally having 1 or 2 hydroxyl, or imidazol-5-yl and Y is cyclopropyl or thiophen-2-yl.

In one preferred embodiment, the present invention provides the compound selected from the group consisting of: Example Nos. 107, 108, 120 and 121listed in Table 7 below, and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compounds.

Table 7

Example No.	structure	compound
107		N-(2-cyclopropyl-7-hydroxy-1H-benzo[d]imidazol-4-yl)-2-(4-hydroxyphenyl)acetamide
108		1-(2-Cyclopropyl-7-hydroxy-1H-benzo[d]imidazol-4-yl)-3-(4-hydroxyphenyl)urea
120		(E)-3-(1H-imidazol-5-yl)-N-(7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-yl) acrylamide
121		N-(7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-yl)-3-(1H-imidazol-5-yl)propanamide

In another preferred embodiment, the present invention provides a compound represented by following formula (I-III) or a salt, hydrate, solvate, or isomer thereof:



(I-III)

wherein

L^1 is -CONH- or a single bond;

L^2 is a single bond;

M is amide or 5-10 membered unsaturated or aromatic heterocyclic group having 1 or 2 hetero atom(s) selected from the group consisting of N, O, and S optionally substituted by 1 or 2 substituent(s) each independently selected from the group A; and

X, Y, and a are defined in the above embodiment represented by formula (I).

In this embodiment, Y is thiophen-2-yl.

In one preferred embodiment, the present invention provides the compound selected from the group consisting of: Example Nos. 65 and 66 listed in Table 8 below, and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compounds.

Table 8

Example No.	structure	compound
65		7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxamide
66		N-[2-(1H-Imidazol-5-yl)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxamide

In another preferred embodiment, the present invention provides a compound represented by following formula (I-IV) or a salt, hydrate, solvate, or isomer thereof :



(I-IV)

wherein

L^1 is -CONH-;

L^2 is a single bond;

M is 5-10 membered unsaturated or aromatic heterocyclic group having 1 or 2 hetero atom(s) selected from the group consisting of N, O, and S optionally substituted by 1 or 2 substituent(s) each independently selected from the group A; and

X, Y, and a are defined as in the embodiment represented by formula (I).

In this embodiment, Y is hydrogen.

In one preferred embodiment, the present invention provides the compound of Example No. 110 listed in Table 9 below, and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compound.

Table 9

Example No.	structure	compound
110		N-[2-(1H-Imidazol-5-yl)ethyl]-7-hydroxy-1H-indole-3-carboxamide

In another preferred embodiment, the present invention provides compounds represented by following formula (I-V), (I-VI) or a salt, hydrate, solvate, or isomer thereof :



(I-V)



(I-VI)

wherein

L^1 is -CONH-;

L^2 is a single bond;

M is 5-10 membered saturated, unsaturated or aromatic heterocyclic group having 1 or 2 hetero atom(s) selected from the group consisting of N, O, and S optionally substituted by 1 or 2 substituent(s) each independently selected from the group A; and

X, Z, and a are defined as in the above embodiment represented by formula (I).

In this embodiment, Z is preferably thiophen-2-ylcarbonylamino.

In one preferred embodiment, the present invention provides the compound of Example Nos. 112 and 122 listed in Table 10 below, and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compound.

Table 10

Example No.	structure	compound
112		N-{5-[2-(1H-Imidazol-5-yl)ethylcarbamoyl]-2-hydroxyphenyl}thiophene-2-carboxamide

122		*N*-(5-hydroxy-2-(piperidin-3-ylcarbamoyl)phenyl)thiophene-2-carboxamide

In another preferred embodiment, the present invention provides a compound represented by formula (I-VI) or a salt, hydrate, solvate, or isomer thereof:



(I-VI)

wherein

Ring A is represented by the formula below;



(II)

M is carboxyl;

X, Y, Z and a are defined as in the above embodiment represented by formula (I).

In this embodiment, ring A is preferably the formula (II).

In one preferred embodiment, the present invention provides the compound of: Example No. 1 listed in Table 11 below, and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compounds.

Table 11

Example No.	Structure	Compound
1		7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid

The compound of formula (I) of the present invention may be in the form of a pharmaceutically acceptable salt derived from an inorganic or organic acid, and representative examples of the pharmaceutically acceptable salt derived from an inorganic or organic acid include salts obtained by adding an inorganic acid such as hydrochloric acid, hydrobromic acid, phosphoric acid or sulfonic acid, or organic carboxylic acids such as acetic acid, trifluoroacetic acid, citric acid, formic acid, maleic acid, oxalic acid, succinic acid, benzoic acid, tartaric acid, fumaric acid,

mandelic acid, ascorbic acid or malic acid, methanesulfonic acid, or para toluenesulfonic acid, which do not limit its scope, to the compound of formula (I). Such acids may be prepared by the conventional processes, and other acids, which themselves are not pharmaceutically acceptable, including oxalic acid may be employed in the preparation of the bases.

Alternatively, the compound of formula (I) of the present invention may also be in the form of a pharmaceutically acceptable salt derived from an inorganic or organic base include salts obtained by adding an inorganic or organic base. For example, alkalis including sodium hydroxide or potassium hydroxide, or alkaline earth metal hydroxides including calcium hydroxide, magnesium hydroxide, aluminum hydroxide or ammonium hydroxide may be used for the preparation of inorganic salt of the compound. Further, organic bases including triethylamine or diisopropylethylamine may also be used for the preparation of organic salt of the compound.

The preferred inventive compound of formula (I-II) and (I-III) may be prepared as in Scheme (I).

Scheme (I)



Wherein, p-TSA is p-toluenesulfonic acid, HATU is 2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate Methanaminium, DIPEA is N,N-diisopropylethylamine and Y (except when Y is a hydrogen), a, L^2 and M have the same meaning as defined previously.

Aniline A is reacted with a nitrile in the presence of p-toluenesulfonic acid to afford amidine B. Amidine B is chlorinated with sodium hypochlorite and cyclized using sodium bicarbonate to form benzimidazole C. Intermediate C is saponified with sodium hydroxide to afford methoxy acid D. Compound D is treated with boron tribromide to afford hydroxy acid E. Hydroxy acid E is reacted with various amines using HATU to afford compounds of formula I-II. Compound D is also reacted with various amines in the presence of HATU to afford amides F. Amides F are treated with boron tribromide to afford compounds of formula (I-III).

The preferred inventive compound of formula (I-IV) can be prepared as shown in Scheme (II).

Scheme (II)



G H

Compound G is reacted with TFAA (trifluoroacetic acid anhydride) followed by hydrolysis with base to afford the intermediate carboxylic acid, which is coupled using HATU to afford compound H. Compound H is hydrogenated to afford compounds of formula (I-VI).

The preferred inventive compound of formula (I-V) can be prepared as shown in Scheme (III).

Scheme (III)



A I

Aniline A is coupled with a carboxylic acid derivative to give the corresponding amide I. The ester and ether are cleaved with boron tribromide and the resulting acid is coupled with an amine derivative to give compounds of formula (I-V).

Scheme (IV)



D J K L M N

Acid D is treated with diphenylphosphoryl azide, triethyl amine and *t*-butanol to afford intermediate J. The boc-group is removed by treatment with hydrogen chloride to afford the amine K. Amine K is treated with the requisite acid in the presence of HATU to afford amide L. Compound L is reacted with boron tribromide to afford the phenol M. Compound M is treated with hydrogen in the presence of palladium to afford compound N (Scheme IV).

Scheme V



O P Q R S

Acid O is coupled with the requisite amine to afford amide P. Compound P is reduced under standard hydrogenation conditions to afford aniline Q. The aniline is reacted with the requisite

acid chloride to afford intermediate R. A final deprotection using boron tribromide affords compound S.

A salt, hydrate, solvate and isomer of the inventive compound of formula (I) may be prepared by employing any of the known methods. The inventive compound of formula (I), a salt, hydrate, solvate or isomer thereof may be used for the treatment of GSK3beta dependent diseases such as Alzheimer disease, mania, depression, migraine and type 2 diabetes, by way of inhibiting GSK3beta activity, the inventive compound having an IC_{50} value (micro M), generally in the range of 0.0001 to 100, for example 0.001 to 50, preferably 0.001 to 10, more preferably 0.001 to 5.

Accordingly, the present invention includes a pharmaceutical composition which includes a therapeutically effective amount of the compound of formula (I), a salt, hydrate, solvate or isomer thereof as an active ingredient and a pharmaceutically acceptable carrier; therefore, the pharmaceutical composition of the present invention exerts superior preventive and treating effects on GSKbeta dependent diseases.

A pharmaceutical formulation may be prepared in accordance with any of the conventional procedures. In preparing the formulation, the active ingredient is preferably admixed or diluted with a carrier, or enclosed within a carrier, sachet or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material acting as a vehicle, excipient or medium for the active ingredient. Thus, the formulations may be in the form of a tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft and hard gelatin capsule, sterile injectable solution, sterile packaged powder and the like.

Examples of suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, and mineral oil. The formulations may additionally include fillers, antiemulsifiers, preservatives and the like. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a mammal by employing any of the procedures well known in the art.

The pharmaceutical composition of the present invention can be administered via various routes including oral, transdermal, subcutaneous, intravenous and intramuscular introduction.

The dosage and method of administration vary according to the body-weight and age of a patient and the administration method; however, one skilled in the art can routinely select a suitable method of administration. If the compound is encodable by a DNA, the DNA can be inserted into a vector for gene therapy and the vector administered to a patient to perform the therapy. The dosage and method of administration vary according to the body-weight, age, and symptoms of the patient; however, one skilled in the art can suitably select them.

For example, although the dose of a compound of the present invention that regulates its activity depends on the symptoms, the dose is generally about 0.1 mg to about 100 mg per day, preferably about 1.0 mg to about 50 mg per day and more preferably about 1.0 mg to about 20 mg per day, when administered orally to a normal adult human (weight 60 kg).

When administering the compound parenterally, in the form of an injection to a normal adult human (weight 60 kg), although there are some differences according to the patient, target organ, symptoms and method of administration, it is convenient to intravenously inject a dose of about 0.01 mg to about 30 mg per day, preferably about 0.1 to about 20 mg per day, and more preferably about 0.1 to about 10 mg per day. In the case of other animals, the appropriate dosage amount may be routinely calculated by converting to 60 kg of body-weight.

Examples

The following examples are intended to further illustrate the present invention without limiting its scope.

Example 1

STEP 1: Synthesis of Methyl 4-Methoxy-3-(thiophene-2-carboximidamido)benzoate



p-Toluenesulfonic acid monohydrate (42 g, 110 mmol) was heated at 120 degrees and once the solid completely melted, it was placed under high vacuum for 1 h to remove the water. The vacuum was released, aniline (20 g, 55 mmol) and 2-thiophenecarbonitrile (24 g, 110 mmol) were added, and the reaction mixture was heated at 160 degrees for 4 h. The reaction mixture was cooled to room temperature followed by addition of satd. aq $NaHCO_3$ (250 mL) and ethyl acetate (250 mL). The layers were separated, the aqueous layer was extracted with ethyl acetate (100 mL), and the combined organic layers were dried over Na_2SO_4, filtered, and concentrated. The crude residue was purified by column chromatography to obtain 16 g of the crude amidine intermediate. The crude intermediate was dissolved in ethyl acetate (350 mL) and HCl (2.0 M in diethyl ether, 55 mL, 110 mmol) was added. The resulting precipitate was filtered to obtain the desired product (16 g, 42% yield) as an off-white solid: ESI MS m/z 291 $[C_{14}H_{14}N_3O_2S + H]^+$.

STEP 2: Synthesis of Methyl 7-Methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylate



To a solution of the product from step 1 (16 g, 49 mmol) in methanol (100 mL) was added 5% aq NaOCl (75 mL, 55 mmol) and the reaction mixture was stirred at room temperature for 2 h. Next, satd. aq $NaHCO_3$ (150 mL) and methanol (150 mL) were added and the resulting reaction mixture was heated at 60 degrees for 2 d. The reaction mixture was cooled to room temperature and concentrated to remove methanol. The reaction mixture was acidified to pH 4 using 6 N HCl and the resulting precipitate was filtered and dried to obtain the desired product (8 g, 57% yield) as a brown solid: ^1H NMR (500 MHz, $CDCl_3$) delta 7.86 (d, J = 8.5 Hz, 1H), 7.71–7.68 (m, 1H), 7.48–7.45 (m, 1H), 7.17–7.14 (m, 1H), 7.73 (d, J = 8.5 Hz, 1H), 4.16 (m, 3H), 3.98 (m, 3H); ESI MS m/z 289 $[C_{14}H_{12}N_2O_3S + H]^+$.

STEP 3: Synthesis of 7-Methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic Acid



To a solution of the product from step 2 (4.2 g, 14 mmol) in ethanol (30 mL) and water (15 mL) was added 6 N NaOH (55 mL) and the reaction mixture was heated at 90 degrees for 2 h. The reaction mixture was cooled and concentrated to dryness. The crude residue was dissolved in water (30 ml) and acidified to pH 4 using 6 N HCl. The resulting precipitate was filtered and dried to obtain the desired product (2.2 g, 58% yield) as a brown solid: ^{1}H NMR (500 MHz, DMSO-d_6) delta 8.25 (d, J = 3.0 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.73–7.68 (m, 1H), 7.22–7.18 (m, 1H), 6.82 (d, J = 8.5 Hz, 1H), 3.97 (m, 3H); ESI MS m/z 275 $[C_{13}H_{10}N_2O_3S + H]^+$.

STEP 4: Synthesis of 7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic Acid



To a solution of the product from step 3 (2.5 g, 9.1 mmol) in dichloroethane (100 mL) was added BBr_3 (23g, 91 mmol) and the reaction mixture was heated at 90 degrees for 2 d. The reaction mixture was cooled and poured onto ice. The resulting solids were filtered to obtain the desired product (0.45 g, 19% yield) as a brown solid. The filtrate was acidified to pH 4 using 6 N HCl and the resulting precipitate was filtered to obtain a second batch of the desired product (Example No. 1, 1.6 g, 88% yield) as a brown solid: ^{1}H NMR (300 MHz, CD_3OD) delta 7.93–7.90 (m, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.62–7.58 (m, 1H), 7.19–7.14 (m, 1H), 6.65 (d, J = 8.1 Hz, 1H); ESI MS m/z 261 $[C_{12}H_8N_2O_3S + H]^+$.

Example 2

STEP 1: Synthesis of Methyl 3-Methoxy-4-(thiophene-2-carboximidamido)benzoate Hydrochloride



Following the procedure outlined for step 1 in Example 1, methyl 4-amino-3-methoxybenzoate (5.0 g, 27 mmol) was reacted with 2-thiophenecarbonitrile (4.4 g, 41 mmol) to afford the desired product (4.5 g, 50 % yield) as a brown solid: ESI MS m/z 291 $[C_{14}H_{14}N_2O_3S + H]^+$.

STEP 2: Synthesis of Methyl 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxylate



Following the procedure outlined for step 2 in Example 1, methyl 3-methoxy-4-(thiophene-2-carboximidamido)benzoate hydrochloride (4.5 g, 13 mmol) was reacted with NaOCl followed by satd. aq $NaHCO_3$ to afford the desired product (3.1 g, 78 % yield) as a brown solid: ^{1}H NMR (300 MHz, DMSO-d_6) delta 13.50 (s, 1H), 13.27 (s, tautomer), 8.05–7.72 (m, 3H), 7.36–7.22 (m, 2H), 4.02 (s, 3H), 3.94 (s, 3H,); ESI MS m/z 289 $[C_{14}H_{12}N_2O_3S + H]^+$.

STEP 3: Synthesis of 7-Methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxylic Acid



Following the procedure outlined for step 3 in Example 1, methyl 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxylate (1.5 g, 5.4 mmol) was reacted with sodium hydroxide to afford the desired product (quant.) as a brown solid: ^{1}H NMR (300 MHz, DMSO-d_6) delta 8.05 (s, J = 3.0 Hz, 1H), 7.83 (d, J = 4.8 Hz, 1H), 7.80 (s, 1H), 7.35 (s, 1H), 7.29–7.26 (m, 1H), 4.01 (s, 3H); ESI MS m/z 275 $[C_{13}H_{10}N_2O_3S + H]^+$.

Example 3

STEP 1: Synthesis of Methyl 3-(Furan-2-carboximidamido)-4-methoxybenzoate Hydrochloride



Following the procedure outlined for step 1 in Example 1, methyl 3-amino-4-methoxybenzoate (10 g, 55.2 mmol) was reacted with 2-furylcarbonitrile (8.0 g, 86 mmol) to afford the desired product (8.5 g, 49% yield) as an off-white solid: ESI MS m/z 275 $[C_{14}H_{14}N_3O_4 + H]^+$.

STEP 2: Synthesis of 2-(Furan-2-yl)-7-methoxy-1H-benzo[d]imidazole-4-carboxylic Acid



To a solution of methyl 3-(furan-2-carboximidamido)-4-methoxybenzoate Hydrochloride (8.5 g, 27 mmol) in methanol (60 mL) was added 5% aq NaOCl (60 mL, 41 mmol) and the reaction mixture was stirred at room temperature for 2 h. Next, satd. aq $NaHCO_3$ (70 mL) and methanol (60 mL) were added and the resulting reaction mixture was heated at 90 degrees for 16 h. Then, 6 N NaOH (50 mL, 300 mmol) was added and the reaction mixture was heated at 90 degrees for an additional 3 h. The reaction mixture was cooled to room temperature and concentrated to remove methanol. The reaction mixture was acidified to pH 5 using 6 N HCl and the resulting precipitate was filtered and dried to afford desired product (4.0 g, 57% yield) as a brown solid: ESI MS m/z 261 $[C_{13}H_{10}N_2O_4 + H]^+$.

STEP 3: Synthesis 2-(Furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic Acid



Following the procedure outlined for step 4 in Example 1, 2-(Furan-2-yl)-7-methoxy-1H-benzo[d]imidazole-4-carboxylic acid (2.0 g, 7.7 mmol) was reacted with boron tribromide (15 g, 60 mmol) to afford the desired product (1.2 g, 63% yield) as a brown solid: ESI MS m/z 245 $[C_{12}H_8N_2O_4 + H]^+$.

Example 4

STEP 1: Synthesis of Methyl 4-fluoro-3-(thiophene-2-carboximidamido)benzoate Hydrochloride



Following the procedure outlined for step 1 in Example, methyl 3-amino-4-fluorobenzoate (5 g, 29.6 mmol) was reacted with 2-thiophenecarbonitrile (6.5 g, 59.2 mmol) to afford the desired product (1.8 g) as a light brown solid: ESI MS m/z 279 $[C_{13}H_{11}FN_2O_2S + H]^+$.

STEP 2: Synthesis of Methyl 7-fluoro-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylate



Following the procedure outlined for step 2 in Example 1, methyl 4-fluoro-3-(thiophene-2-carboximidamido)benzoate hydrochloride (1.7 g, 6.0 mmol) was reacted with 5% aq NaOCl and satd. aq $NaHCO_3$ to afford the desired product (0.21 g, 3% yield) as a yellow solid: ESI MS m/z 277 $[C_{13}H_9FN_2O_2S + H]^+$.

STEP 3: Synthesis of 7-Fluoro-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic Acid



Following the procedure outlined for step 4 in Example 1, methyl 7-fluoro-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylate (0.2 g, 0.7 mmol) was reacted

with 3 N NaOH (10 mL) to afford the desired product (0.1 g crude) as an off-white solid: ESI MS m/z 263 $[C_{12}H_7FN_2O_2S + H]^+$.

Example 5

STEP 1: Synthesis of Methyl 3-(Cyclopropanecarboximidamido)-4-methoxybenzoate Hydrochloride



Following the procedure outlined for step 1 in Example 1, methyl 3-amino-4-methoxybenzoate (10 g, 55 mmol) was reacted with cyclopropanecarbonitrile (7.4 g, 110 mmol) to afford the desired product (16 g crude) as a black solid: ESI MS m/z 249 $[C_{13}H_{16}N_2O_3 + H]^+$.

STEP 2: Synthesis of Methyl 2-Cyclopropyl-7-methoxy-1*H*-benzo[*d*]imidazole-4-carboxylate



Following the procedure outlined for step 2 in Example 1, methyl 3-(cyclopropanecarboximidamido)-4-methoxybenzoate hydrochloride (15 g, 50 mmol) was reacted with aq NaOCl followed by satd. aq $NaHCO_3$ to afford the desired product (12 g crude) as a brown solid: ESI MS *m/z* 247 $[C_{13}H_{14}N_2O_3 + H]^+$.

STEP 3: Synthesis of 2-Cyclopropyl-7-methoxy-1H-benzo[d]imidazole-4-carboxylic Acid



Following the procedure outlined for step 3 in Example 1, methyl 2-cyclopropyl-7-methoxy-1*H*-benzo[*d*]imidazole-4-carboxylate (2.0 g, 8.0 mmol) was reacted with sodium hydroxide to afford the desired product (1.7 g crude) as a black solid: ESI MS m/z 233 $[C_{12}H_{12}N_2O_3 + H]^+$.

STEP 4: Synthesis of 2-Cyclopropyl-7-hydroxy-1*H*-benzo[d]imidazole-4-carboxylic Acid



Following the procedure outlined for step 4 in Example 1, 2-cyclopropyl-7-methoxy-1H-benzo[d]imidazole-4-carboxylic acid (1.5 g, 6.1 mmol) was reacted with boron tribromide to afford the desired product (1.2 g crude) as a black solid: ESI MS *m/z* 219 $[C_{11}H_{10}N_2O_3 + H]^+$.

Example 6

STEP 1: Synthesis of Methyl 3-(Cyclopentanecarboximidamido)-4-methoxybenzoate Hydrochloride



Following the procedure outlined for step 1 in Example 1, methyl 3-amino-4-methoxybenzoate (5.0 g, 27 mmol) was reacted with cyclopentanecarbonitrile (5.2 g, 55 mmol) to afford the desired product (7.7 g crude) as a brown solid: ESI MS m/z 277 $[C_{15}H_{20}N_2O_3 + H]^+$.

STEP 2: Synthesis of Methyl 2-Cyclopentyl-7-methoxy-1H-benzo[d]imidazole-4-carboxylate



Following the procedure outlined for step 2 in Example 1, methyl 3-(cyclopentanecarboximidamido)-4-methoxybenzoate hydrochloride (5.6 g, 18 mmol) was reacted with aq NaOCl followed by satd. aq $NaHCO_3$ to afford the desired product (4.9 g crude) as a black solid: ESI MS m/z 275 $[C_{15}H_{18}N_2O_3 + H]^+$.

STEP 3: Synthesis of 2-Cyclopentyl-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic Acid



Following the procedure outlined for step 4 in Example 1, methyl 2-cyclopentyl-7-methoxy-1H-benzo[d]imidazole-4-carboxylate (1.1 g, 4.0 mmol) was reacted

with boron tribromide to afford the desired product (0.92 g crude) as a black solid: ESI MS m/z 247 $[C_{13}H_{14}N_2O_3 + H]^+$.

Example 7

STEP 1: Synthesis of Methyl 3-Benzimidamido-4-methoxybenzoate Hydrochloride



Following the procedure outlined for step 1 in Example 1, methyl 3-amino-4-methoxybenzoate (5.0 g, 27 mmol) was reacted with benzonitrile (5.7 g, 55 mmol) to afford the desired product (7.8 g crude) as a black solid: ESI MS m/z 285 $[C_{16}H_{16}N_2O_3+ H]^+$.

STEP 2: Synthesis of Methyl 7-Methoxy-2-phenyl-1H-benzo[d]imidazole-4-carboxylate



Following the procedure outlined for step 2 in Example 1, methyl 3-benzimidamido-4-methoxybenzoate hydrochloride (2.0 g, 8.0 mmol) was reacted with aq NaOCl followed by satd. aq $NaHCO_3$ to afford the desired product (1.7 g crude) as an off-white solid: ESI MS m/z 283 $[C_{16}H_{14}N_2O_3 + H]^+$.

STEP 3: Synthesis of 7-Hydroxy-2-phenyl-1*H*-benzo[d]imidazole-4-carboxylic Acid



Following the procedure outlined for step 4 in Example 1, methyl 7-methoxy-2-phenyl-1H-benzo[d]imidazole-4-carboxylate (4.0 g, 12 mmol) was reacted with boron tribromide to afford the desired product (2.1 g, crude) as a black solid: ESI MS *m/z* 255 $[C_{14}H_{10}N_2O_3 + H]^+$.

General Procedure A – synthesis of compounds of formula I-II as described in Scheme (1):

To a solution of acid (1.0 equiv) in DMF (5-10 mL) was added HATU (1.2-1.5 equiv), DIPEA (3.0-5.0 equiv), and the amine (1.5-2.0 equiv) and the reaction mixture was either stirred at room temperature for 16 h or heated at 50-70 degrees for 16 h. The reaction mixture was diluted with

satd. aq $NaHCO_3$ (20 mL) and extracted with ethyl acetate (3x20 mL). The combined organic layer was dried over Na_2SO_4, concentrated, and purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA). The desired product was obtained as the trifluoroacetic acid salt which was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to obtain the desired products. In some instances the desired product was treated with TFA (1-2 mL) for 1 h, concentrated and purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA). The desired product was obtained as the trifluoroacetic acid salt which was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to obtain the desired products

Example 8

7-Hydroxy-N-(4-sulfamoylbenzyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure A,
7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (125 mg, 0.36 mmol) was reacted with 4-(aminomethyl)benzenesulfonamide (0.13 g, 0.72 mmol) to afford the desired product (30 mg, 19% yield) as a light yellow solid: ^{1}H NMR (300 MHz, CD_3OD) delta 7.94–7.79 (m, 4H), 7.67–7.59 (m, 3H), 7.20–7.16 (m, 1H), 6.71 (d, J = 8.1 Hz, 1H), 4.82 (s, 2H); ESI MS m/z 429 $[C_{19}H_{16}N_4O_4S_2 + H]^+$; HPLC 98.4% (AUC), t_R = 11.94 min.

Example 9

N-(2,4-Difluorobenzyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure A,
7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (125 mg, 0.36 mmol) was reacted with (2,4-difluorophenyl)methanamine (0.10 g, 0.72 mmol) to afford the desired product (33 mg, 24% yield) as an off-white solid: ^{1}H NMR (300 MHz, CD_3OD) delta 7.85–7.78 (m, 2H), 7.62–7.57 (m, 2H), 7.20–7.17 (m, 1H), 7.01–6.95 (m, 2H), 6.71 (d, J = 8.4 Hz, 1H), 4.75 (s, 2H); ESI MS m/z 368 $[C_{19}H_{13}F_2N_3O_2S + H]^+$; HPLC 96.2% (AUC), t_R = 14.47 min.

Example 10

7-Hydroxy-*N*-(thiazol-2-yl)-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide



Following General Procedure A,
5 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (146 mg, 0.43 mmol) was reacted with thiazol-2-amine (0.072 g, 0.72 mmol) to afford the desired product (15 mg, 10% yield) as a light brown solid: ^{1}H NMR (300 MHz, CD_3OD) delta 8.02–8.00 (m, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.69 (d, J = 5.1 Hz, 1H), 7.54–7.53 (m, 1H), 7.25–7.17 (m, 2H), 6.79 (d, J = 8.4 Hz, 1H); ESI MS m/z 343 $[C_{15}H_{10}N_4O_2S_2 + H]^+$; HPLC >99% (AUC), t_R = 14.10 min.

10

Example 11

7-Hydroxy-N-[2-(pyridin-2-ylamino)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



15

Following General Procedure A,
7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.24 g, 0.91 mmol) was reacted with N^1-(pyridin-2-yl)ethane-1,2-diamine (0.098 g, 0.72 mmol) to afford the desired product (114 mg, 33% yield) as a white solid: ^{1}H NMR (500 MHz, DMSO–d_6) 8.00–7.96 (m,
20 2H), 7.72–7.70 (m, 2H), 7.36 (dd, J = 3.0, 1.5 Hz, 1H), 7.21 (t, J = 4.0 Hz, 1H), 6.73 (d, J = 8.5 Hz, 1H), 6.53 (d, J = 8.5 Hz, 1H), 6.48 (t, J = 1.0 Hz, 1H), 3.62 (t, J = 6.5 Hz, 2H), 3.48 (t, J = 6.5 Hz, 2H); ESI MS m/z 380 $[C_{19}H_{17}N_5O_2S + H]^+$; HPLC >99% (AUC), t_R = 11.12 min.

Example 12

25 7-Hydroxy-N-[3-(2-hydroxyethylamino)propyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure A,
7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.15 g, 0.58 mmol) was reacted with 2-(3-aminopropylamino)ethanol (0.084 g, 0.72 mmol) to afford the desired product (31 mg, 15% yield) as a yellow-brown solid: ^{1}H NMR (500 MHz, CD_3OD) 7.86 (dd, J = 3.5, 1.0 Hz, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.62 (dd, J = 5.0, 1.0 Hz, 1H), 6.66 (d, J = 8.5 Hz, 1H), 3.73 (t, J = 5.0 Hz, 2H), 3.64 (t, J = 6.5 Hz, 2H), 2.99 (t, J = 7.0 Hz, 2H), 2.94 (t, J = 5.5 Hz, 2H), 2.02–1.99 (m, 2H); ESI MS m/z 361 $[C_{17}H_{20}N_4O_3S + H]^+$.

Example 13

(S)-Methyl 2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(1H-imidazol-5-yl)propanoate



Following General Procedure A,
7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.57 mmol) was reacted with (S)-methyl 2-amino-3-(1H-imidazol-5-yl)propanoate (0.12 g, 0.72 mmol) to afford the desired product (66 mg, 23% yield) as a light yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.85 (d, J = 3.6 Hz, 1H),7.74 (d, J = 8.3 Hz, 1H), 7.62 (d, J = 4.2 Hz, 1H) 7.58 (s, 1H) 7.19 (t, J = 4.9 Hz, 1H), 7.03 (s, 1H), 6.69 (d, J = 8.3 Hz, 1H) 5.01–4.99 (m, 1H), 3.77 (s, 3H); ESI MS m/z 412 $[C_{19}H_{17}N_5O_4S + H]^+$; HPLC 96.3% (AUC), t_R = 7.94 min.

Example 14

(S)-Methyl 2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(1H-indol-3-yl)propanoate



Following General Procedure A, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.57 mmol) was reacted with (S)-methyl 2-amino-3-(1H-indol-3-yl)propanoate (0.16 g, 0.72 mmol) to afford the desired product (65 mg, 13% yield) as a light yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.77–7.58 (m, 2H), 7.58–7.56 (m, 2H), 7.28 (d, J = 6.0 Hz, 2H), 7.16 (t, J = 4.9 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 6.94 (t, J = 15.1 Hz, 1H), 6.68 (d, J = 8.3 Hz, 1H), 5.04 (t, J = 6.3 Hz, 1H), 3.69 (s, 3H) 3.45 (d, J = 6.25 Hz, 2H); ESI MS m/z 461 $[C_{24}H_{20}N_4O_4S + H]^+$; HPLC 98.7% (AUC), t_R = 13.03 min.

Example 15

Methyl 3-Hydroxy-2-[7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]propanoate



Following General Procedure A, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.57 mmol) was reacted with methyl 2-amino-3-hydroxypropanoate (0.084 g, 0.72 mmol) to afford the desired product (20 mg, 10% yield) as a light yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.94 (d, J = 3.2 Hz, 1H), 7.80 (d, J = 8.3 Hz, 1H), 7.67 (d, J = 4.8 Hz, 1H), 7.21 (d, J = 4.8 Hz, 1H), 6.73 (d, J = 8.3 Hz, 1H), 4.11–4.05 (m, 1H), 4.01–3.98 (m, 1H), 3.82 (s, 3H); ESI MS m/z 362 $[C_{16}H_{15}N_3O_5S + H]^+$; HPLC 95.0% (AUC), t_R = 11.36 min.

Example 16

Methyl 2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(4-hydroxyphenyl)propanoate



Following General Procedure A, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.57 mmol) was reacted with methyl 2-amino-3-(4-hydroxyphenyl)propanoate (0.14 g, 0.72 mmol) to afford the desired product (15 mg, 6% yield) as a light yellow solid: ^{1}H NMR (500 MHz, DMSO-d_6) delta 13.45 (s, 1H), 10.86 (s,1H), 9.85 (d, J = 6.8 Hz, 1H), 9.18 (s, 1H), 8.07 (d, J = 3.6 Hz, 1H), 7.81 (d, J = 5.0 Hz, 1H), 7.65 (d, J = 8.3 Hz, 1H), 7.27 (t, J = 4.9 Hz, 1H), 7.16 (d, J = 8.4 Hz, 2H), 6.72 (d, J = 8.2 Hz, 1H), 6.67 (d, J = 8.4 Hz, 2H), 4.71–4.68 (m, 1H), 3.64 (s, 3H), 3.16–3.10 (m, 1H), 3.01–2.96 (m, 1H); ESI MS m/z 362 $[C_{16}H_{15}N_3O_5S + H]^+$; HPLC 95.0% (AUC), t_R = 11.36 min.

Example 17

(R)-7-Hydroxy-N-[1-hydroxy-3-(1H-imidazol-4-yl)propan-2-yl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure A, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.57 mmol) was reacted with (R)-2-amino-3-(1H-imidazol-4-yl)propan-1-ol (0.10 g, 0.72 mmol) to afford the desired product (41 mg, 18% yield) as a light yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.86 (d, J = 3.6 Hz, 1H), 7.73 (d, J = 8.3 Hz, 1H), 7.62 (d, J = 5.0 Hz, 1H), 7.59 (s, 1H), 7.20–7.18 (m, 1H), 6.96 (s, 1H), 6.68 (d, 1H), 4.44–4.41 (m, 1H), 3.75 (d, J = 4.8 Hz, 2H), 3.16–3.09 (m, 1H), 3.04–3.00 (m, 1H); ESI MS m/z 383 $[C_{18}H_{17}N_5O_3S + H]^+$.

Example 18

(S)-7-Hydroxy-N-(1-hydroxy-3,3-dimethylbutan-2-yl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure A, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.57 mmol) was reacted with (S)-2-amino-3,3-dimethylbutan-1-ol (0.084 g, 0.72 mmol) to afford the desired product (24 mg, 12% yield) as a light yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.86 (d, J = 3.6 Hz, 1H), 7.80 (d, J = 8.3 Hz, 1H), 7.60 (d, J = 5.0 Hz, 1H), 7.19 (t, J = 5.0 Hz, 1H), 6.71 (d, J = 8.3 Hz, 1H), 4.08–4.06 (m, 1H), 3.96–3.93 (m, 1H), 3.73–3.69 (m, 1H), 1.14 (s, 9H); ESI MS m/z 362 $[C_{18}H_{21}N_3O_3S + H]^+$; HPLC > 99% (AUC), t_R = 13.85 min.

Example 19

(S)-7-Hydroxy-N-(1-hydroxy-3-phenylpropan-2-yl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure A, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (200 mg, 0.73 mmol) was reacted with (S)-2-amino-3-phenylpropan-1-ol (0.11 g, 0.72 mmol) to afford the desired product (55 mg, 19% yield) as a light yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.87 (d, J = 3.7 Hz, 1H), 7.73 (d, J = 8.3 Hz, 1H), 7.63 (d, J = 4.0 Hz, 1H), 7.38 (d, J = 7.1 Hz, 2H), 7.21–7.19 (m, 3H), 7.11 (t, J = 13.6 Hz, 1H), 6.67 (d, J = 8.3 Hz, 1H), 4.40–4.37 (m, 1H), 3.75–3.68 (m, 2H), 3.16–3.12 (m, 1H) 3.01–2.97 (m, 1H); ESI MS m/z 394 $[C_{21}H_{19}N_3O_3S + H]^+$; HPLC > 99% (AUC), t_R = 13.67 min.

Example 20

7-Hydroxy-2-(thiophen-2-yl)-N-[2-(thiophen-2-yl)ethyl]-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure A, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.577 mmol) was reacted with 2-(thiophen-2-yl)ethanamine (0.087 g, 0.72 mmol) to afford the desired product (42 mg, 20% yield) as a light yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.82 (d, J = 3.3 Hz, 1H) 7.79 (d, J = 8.3 Hz, 1H), 7.62–7.61 (m, 1H), 7.18 (t, J = 9.9 Hz, 2H), 6.99 (s, 1H), 6.91 (t, J = 8.6 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 3.81 (t, J = 6.7 Hz, 2H), 3.23 (t, J = 6.7 Hz, 2H); ESI MS m/z 370 $[C_{18}H_{15}N_3O_2S_2 + H]^+$; HPLC > 99% (AUC), t_R = 12.80 min.

Example 21

7-Hydroxy-N-(4-sulfamoylphenethyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure A, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.577 mmol) was reacted with 4-(2-aminoethyl)benzenesulfonamide (0.14 g, 0.72 mmol) to obtain the desired product (18.3 mg, 7%) as an off-white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.83–7.81 (m, 3H), 7.76 (d, J = 8.1 Hz, 1H) 7.62 (d, J = 4.8 Hz, 1H), 7.54 (d, J = 7.6 Hz, 2H), 7.18 (t, J = 8.8 Hz, 1H), 6.68 (d, J = 8.2 Hz, 1H), 3.85 (t, J = 11.5 Hz, 2H), 3.11 (t, J = 6.1 Hz, 2H); ESI MS m/z 443 $[C_{20}H_{18}N_4O_4S_2 + H]^+$; HPLC >99% (AUC), t_R = 12.14 min.

Example 22

7-Hydroxy-N-(3-methoxyphenethyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure A, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.58 mmol) was reacted with 2-(3-methoxyphenyl)ethanamine (0.11 g, 0.72 mmol) to obtain the desired product (24 mg, 11% yield) as a light yellow solid: ^{1}H NMR (500 MHz, DMSO-d_6) delta 8.14 (d, J = 0.5 Hz, 1H), 8.00 (d, J = 1.0 Hz, 1H), 7.78 (d, J = 4.0 Hz, 1H), 7.77–7.17 (m, 2H), 6.93–6.82 (m, 2H), 6.75–6.70 (m, 1H). 3.73–3.65 (m, 5H), 2.92–2.82 (m, 2H); ESI MS m/z 394 [$C_{21}H_{19}N_3O_3S$ + H]$^+$; HPLC 95.7% (AUC), t_R = 14.24 min.

Example 23

7-hydroxy-N-(3-methoxyphenethyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure A, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.58 mmol) was reacted with 2-(4-methoxyphenyl)ethanamine (0.11 g, 0.72 mmol) to obtain the desired product (30 mg, 9% yield) as a light yellow solid: ^{1}H NMR (500 MHz, DMSO-d_6) 8.01 (d, J = 3.5 Hz, 1H), 7.81 (s, 1H), 7.77 (d, J = 5.0, 1H), 7.26–7.23 (m, 3H), 6.86–6.82 (m, 2H), 6.73–6.70 (m, 2H), 3.71–3.63 (m, 5H), 2.87–2.63 (m, 2H); ESI MS m/z 394 [$C_{21}H_{19}N_3O_3S$ + H]$^+$; HPLC 94.5% (AUC), t_R = 14.29 min.

General Procedure B – synthesis of amides F as described in Scheme (1):

To a suspension of 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (1.0 equiv) in toluene (5-15 mL) was added thionyl chloride (4.0 equiv). After stirring at room temperature for 16 h, the reaction mixture was heated at 70 degrees for 2 h. The reaction mixture was cooled, and concentrated, and the residue was suspended in THF (10-20 mL) followed by the addition of pyridine (2.0 equiv) and the corresponding amine (2.0 equiv) and the reaction mixture was heated at 70 degrees for 16 h. The reaction mixture was concentrated and the residue was diluted with water (20 mL) and extracted with ethyl acetate (3x20 mL). The combined organic layers were washed with satd. aq $NaHCO_3$ (20 mL), concentrated, and purified by flash chromatography (silica, 0-15% methanol/dichloromethane) to afford amides F. In

most cases these intermediates were isolated as crude products and were carried forward without extensive characterization or further purification.

Example 24

7-Methoxy-N-[2-(1-methyl-1H-imidazol-5-yl)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (170 mg, 0.62 mmol) was reacted with 2-(1-methyl-1H-imidazol-5-yl)ethanamine (0.15 g, 1.2 mmol) to afford the desired product (170 mg) as a yellow solid: ESI MS m/z 382 $[C_{19}H_{19}N_5O_2S + H]^+$.

Example 25

N-[2-(Dimethylamino)ethyl]-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (160 mg, 0.58 mmol) was reacted with N^1,N^1-dimethylethane-1,2-diamine (0.10 g, 1.2 mmol) to afford the desired product (136 mg) as a brown glass: ESI MS m/z 345 $[C_{17}H_{20}N_4O_2S + H]^+$.

Example 26

N-(3,4-Dimethoxybenzyl)-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B,
7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (158 mg, 0.58 mmol) was reacted with (3,4-dimethoxyphenyl)methanamine (0.20 g, 1.2 mmol) to afford the desired product (248 mg) as a brown solid: ESI MS m/z 424 $[C_{22}H_{21}N_3O_4S + H]^+$.

Example 27

7-Methoxy-N-[2-(phenylsulfonamido)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide.



Following General Procedure B,
7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.18 g, 0.65 mmol) was reacted with N-(2-aminoethyl)benzenesulfonamide (0.26 g, 1.3 mmol) to afford the desired product (0.15 g, 51% yield) as an off-white solid: ESI MS m/z 457 $[C_{21}H_{20}N_4O_4S_2 + H]^+$.

Example 28

N-[2-(4-Chlorophenylsulfonamido)ethyl]-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B,
7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.20 g, 0.73 mmol) was reacted with N-(2-aminoethyl)-4-chlorobenzenesulfonamide (0.34 g, 1.5 mmol) to afford the desired product (0.16 g, 45% yield) as an off-white solid: ESI MS m/z 491 $[C_{21}H_{19}ClN_4O_4S_2 + H]^+$.

Example 29

7-Methoxy-N-[2-(pyridine-4-sulfonamido)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.20 g, 0.73 mmol) was reacted with N-(2-aminoethyl)pyridine-4-sulfonamide (0.29 g, 1.5 mmol) to afford the desired product (0.069 g, 21% yield) as an off-white solid: ESI MS m/z 458 $[C_{20}H_{19}N_5O_4S_2 + H]^+$.

Example 30

7-Methoxy-N-[2-(4-methylbenzamido)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.20 g, 0.73 mmol) was reacted with N-(2-aminoethyl)-4-methylbenzamide (0.27 g, 1.5 mmol) to afford the desired product (0.24 g, 76% yield) as an off-white solid: ESI MS m/z 435 $[C_{23}H_{22}N_4O_3S + H]^+$.

Example 31

N-(2-Acetamidoethyl)-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.10 g, 0.36 mmol) was

reacted with N-(2-aminoethyl)acetamide (0.073 g, 0.72 mmol) to afford the crude desired product as an off-white solid: ESI MS m/z 356 $[C_{17}H_{18}N_4O_3S + H]^+$.

Example 32

N-[3-(Isopropylamino)propyl]-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.20 g, 0.73 mmol) was reacted with N^1-isopropylpropane-1,3-diamine (0.17 g, 1.5 mmol) to afford the desired product as an off-white solid: ESI MS m/z 373 $[C_{19}H_{24}N_4O_2S + H]^+$.

Example 33

N-(4-Fluorophenethyl)-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.20 g, 0.73 mmol) was reacted with 2-(4-fluorophenyl)ethanamine (0.21 g, 1.5 mmol) to afford the desired product (0.14 g) as an off-white solid: ESI MS m/z 396 $[C_{21}H_{18}FN_3O_2S + H]^+$.

Example 34

N-(4-Hydroxyphenethyl)-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.20 g, 0.73 mmol) was reacted with 4-(2-aminoethyl)phenol (0.20 g, 1.5 mmol) to afford the desired product (0.31 g) as an off-white solid: ESI MS m/z 393 $[C_{21}H_{19}N_3O_3S + H]^+$.

General Procedure C – synthesis of compounds of formula (I-III) as described in Scheme (1): To a suspension of amides F (1.0 equiv) in dichloroethane (10-25 mL) was added boron tribromide (6.0-10 equiv) and the reaction mixture was heated at 80 degrees for 16 h. The reaction mixture was poured over ice and the resulting mixture was concentrated. The crude residue was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) as a crude purification. The crude product was further purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA). The desired product was obtained as the trifluoroacetic acid salt which was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to obtain the desired products.

Example 35

7-Hydroxy-N-[2-(1-methyl-1H-imidazol-5-yl)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide.



Following General Procedure C, 7-Methoxy-*N*-[2-(1-methyl-1*H*-imidazol-5-yl)ethyl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide (170 mg) was reacted with boron tribromide to afford the desired product (36 mg, 16% yield) as a white solid: ^{1}H NMR (300 MHz, DMSO-d_6) delta 13.40 (s, 1H), 10.78 (s, 1H), 9.55 (s, 1H), 8.03 (s, 1H), 7.79–7.69 (m, 2H), 7.51 (s, 1H), 7.26–7.23 (m, 1H), 6.96 (s, 1H), 6.72 (d, J = 8.1 Hz, 1H), 3.68–3.66 (m, 2H), 3.56 (s, 3H), 2.76 (t, J = 6.9 Hz, 1H); ESI MS m/z 368 $[C_{18}H_{17}N_5O_2S + H]^+$; HPLC >99% (AUC), t_R = 10.67 min.

Example 36

N-[2-(dimethylamino)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, *N*-[2-(Dimethylamino)ethyl]-7-methoxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide (136 mg) was reacted with boron tribromide to afford the desired product (69 mg, 35% yield) as a light yellow solid: ^{1}H NMR (300 MHz, CD_3OD) delta 7.88–7.87 (m, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.64–7.62 (m, 1H), 7.22–7.19 (m, 1H), 6.68 (d, J = 8.4 Hz, 1H), 3.69 (t, J = 6.6 Hz, 2H), 2.75 (t, J = 6.6 Hz, 1H), 2.43 (s, 6H); ESI MS m/z 331 $[C_{16}H_{18}N_4O_2S + H]^+$; HPLC >99% (AUC), t_R = 8.68 min.

Example 37

N-(3,4-Dihydroxybenzyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, *N*-(3,4-Dimethoxybenzyl)-7-methoxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide (248 mg) was reacted with boron tribromide to afford the desired product (18 mg, 8% yield) as a brown solid: ^{1}H NMR (300 MHz, CD_3OD) delta 7.98–7.97 (m, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 4.5 Hz, 1H), 7.28–7.25 (m, 1H), 6.90 (s, 1H), 6.83–6.77 (m, 3H), 4.55 (s, 2H); ESI MS m/z 382 $[C_{19}H_{15}N_3O_4S + H]^+$; HPLC 97.0% (AUC), t_R = 11.73 min.

Example 38

7-Hydroxy-N-[2-(phenylsulfonamido)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, 7-Methoxy-*N*-[2-(phenylsulfonamido)ethyl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide (150 mg) was reacted with boron tribromide to afford the desired product (36 mg, 37% yield) as an off-white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.91 (t, J = 3.6 Hz, 1H), 7.82 (d, J = 7.5 Hz, 2H), 7.74 (d, J = 8.2 Hz, 1H), 7.64 (d, J = 4.9 Hz, 1H), 7.40 (t, J = 7.1 Hz, 1H), 7.34–7.31(m, 2H), 7.21 (dd, J = 5.0, 3.7 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 3.60 (t, J = 6.1 Hz, 2H), 3.19 (t, J = 5.9 Hz, 2H); ESI MS m/z 443 $[C_{20}H_{18}N_4O_4S_2 + H]^+$; HPLC >99% (AUC), t_R = 12.63 min.

Example 39

N-[2-(4-Chlorophenylsulfonamido)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, *N*-[2-(4-Chlorophenylsulfonamido)ethyl]-7-methoxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide (160 mg) was reacted with boron tribromide to afford the desired product (17 mg, 18% yield) as an off-white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.90 (d, J = 0.9 Hz, 1H), 7.74–7.69 (m, 3H), 7.64 (d, J = 4.8 Hz, 1H), 7.22 (t, J = 3.9 Hz, 1H), 7.14 (d, J = 8.4 Hz, 2H), 6.69 (d, J = 8.4 Hz, 1H), 3.59–3.57 (m, 2H), 3.26–3.24 (m, 2H); ESI MS m/z 477 $[C_{20}H_{17}ClN_4O_4S_2 + H]^+$; HPLC >99% (AUC), t_R = 13.39 min.

Example 40

7-Hydroxy-N-[2-(pyridine-4-sulfonamido)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, 7-Methoxy-*N*-[2-(pyridine-4-sulfonamido)ethyl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide (69 mg) was reacted with boron tribromide to afford the desired product (14 mg, 21% yield) as an off-white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 8.93 (d, J = 2.0 Hz, 1H), 8.52 (d, J = 4.2 Hz, 1H), 8.19 (d, J = 8.0 Hz, 1H), 8.02 (d, J = 3.4 Hz, 1H), 7.80 (d, J = 5.0 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.39–7.35 (m, 1H), 7.29 (dd, J = 4.9, 3.9 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 3.58 (t, J = 6.0 Hz, 2H), 3.27–3.25 (m, 2H); ESI MS m/z 444 $[C_{19}H_{17}N_5O_4S_2 + H]^+$; HPLC 98.5% (AUC), t_R = 11.28 min.

Example 41

7-Hydroxy-N-[2-(4-methylbenzamido)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, 7-Methoxy-*N*-[2-(4-methylbenzamido)ethyl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide (0.24 g) was reacted with boron tribromide to afford the desired product (165 mg, 71% yield) as an off-white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 8.26 (dd, J = 3.8, 1.0 Hz, 1H), 8.10 (dd, J = 5.0, 1.0 Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.70 (d, J = 8.2 Hz, 2H), 7.42 (dd, J = 4.9, 3.9 Hz, 1H), 7.23 (d, J = 8.0 Hz, 2H), 6.96 (d, J = 8.4 Hz, 1H), 3.68 (s, 4H), 2.35 (s, 3H); ESI MS m/z 421 $[C_{19}H_{17}N_5O_4S_2 + H]^+$; HPLC 95.8% (AUC), t_R = 12.69 min.

Example 42

N-(2-Acetamidoethyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, *N*-(2-Acetamidoethyl)-7-methoxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide (73 mg) was reacted with boron tribromide to afford the desired product (28 mg, 25% yield) as a light brown solid: ^{1}H NMR (500 MHz, CD_3OD) 7.88 (d, J = 3.5 Hz, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.63 (d, J = 5.0 Hz, 1H), 7.20 (t, J = 4.5 Hz, 1H), 6.70 (d, J = 8.0 Hz, 1H), 3.67 (t, J = 6.0 Hz, 2H), 3.47 (t, J = 6.0 Hz, 2H), 1.96 (s, 3H); ESI MS m/z 345 $[C_{16}H_{16}N_4O_3S + H]^+$.

Example 43

N-[3-(Isopropylamino)propyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, *N*-[3-(Isopropylamino)propyl]-7-methoxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide (170 mg) was reacted with boron tribromide to afford the desired product (32 mg, 12% yield) as a light brown solid: ^{1}H NMR (500 MHz, DMSO–d_6) 9.50 (s, 1H), 8.06 (d, J = 2.5 Hz, 1H), 7.76 (d, J = 4.5 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.23 (dd, J = 5.0, 4.0 Hz, 1H), 6.68 (d, J = 8.0 Hz, 1H), 3.46 (t, J = 6.0 Hz, 2H), 2.81–2.78 (m, 1H), 2.72 (t, J = 7.0 Hz, 2H), 1.75–1.72 (m, 6H); ESI MS m/z 359 $[C_{17}H_{18}N_4O_3S + H]^+$; HPLC 98.2% (AUC), t_R = 8.30 min.

Example 44

N-(4-Fluorophenethyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, *N*-(4-Fluorophenethyl)-7-methoxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide (140 mg) was reacted with boron tribromide to afford the desired product (17 mg, 13% yield) as a light brown solid: ^{1}H NMR (500 MHz, DMSO–d_6) 7.67 (bs, 1H), 7.41–7.36 (m, 4H), 7.10–7.07 (m, 3H), 6.17 (d, J = 7.5 Hz, 1H), 3.63–3.60 (m, 2H), 2.90 (t, J = 7.0 Hz, 2H); ESI MS m/z 382 $[C_{20}H_{16}FN_3O_2S + H]^+$; HPLC 92.4% (AUC), t_R = 14.48 min.

Example 45

7-Hydroxy-N-(4-hydroxyphenethyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, *N*-(4-Hydroxyphenethyl)-7-methoxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide (310 mg) was reacted with boron tribromide to afford the desired product (19 mg, 7% yield) as a brown solid: ^{1}H NMR (500 MHz, CD_3OD) 7.79–7.74 (m, 2H), 7.61–7.60 (m, 1H), 7.19–7.15 (m, 3H), 6.71–6.65 (m, 3H), 3.74–3.71 (m, 2H), 2.92–2.89 (m, 2H); ESI MS m/z 380 $[C_{20}H_{17}N_3O_3S + H]^+$; HPLC >99% (AUC), t_R = 12.54 min.

Example 46

N-(2-Hydroxyethyl)-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



A suspension of methyl 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylate (970 mg, 3.36 mmol) in ethanolamine (5 mL) was heated at 100 degrees for 18 h. The reaction mixture was cooled and diluted with water (50 mL). The resulting precipitate was filtered and washed with water to afford the desired product (850 mg, 80% yield) as a brown solid: ESI MS m/z 318 $[C_{15}H_{15}N_3O_3S + H]^+$.

Example 47

N-[2-(5-Carbamoylpyridin-2-yloxy)ethyl]-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



To a solution of 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylate (100 mg, 0.31 mmol) in DMF (5 mL) was added NaH (60 mg, 1.5 mmol, 60% dispersion) and the suspension was stirred at room temperature for 1 h. Following the addition of 6-chloro-nicotinamide (74 mg, 0.47 mmol), the reaction mixture was heated at 85 degrees for 18 h. The reaction mixture was cooled and quenched with water (20 mL) and the pH was adjusted to 7. The resulting precipitate was filtered and washed with water to afford the desired product (105 mg, crude) as a brown solid: ESI MS m/z 438 $[C_{21}H_{19}N_5O_4S + H]^+$.

Example 48

7-methoxy-2-(thiophen-2-yl)-N-(2-(5-(trifluoromethyl)pyridin-2-yloxy)ethyl)-1H-benzo[d]imidazole-4-carboxamide



To a solution of 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylate (125 mg, 0.39 mmol) in DMF (5 mL) was added NaH (75 mg, 1.95 mmol, 60% dispersion) and the suspension was stirred at room temperature for 1 h. Following the addition of 2-chloro-5-trifluoromethyl-pyridine (143 mg, 0.78 mmol), the reaction mixture was heated at 85 degrees for 18 h. The reaction mixture was cooled and quenched with water (20 mL) and the pH was adjusted to 7. The resulting precipitate was filtered and washed with water to afford the desired product (180 mg, crude) as a brown solid: ESI MS m/z 463 $[C_{21}H_{17}F_3N_4O_3S + H]^+$.

Example 49

N-[2-(5-Carbamoylpyridin-2-yloxy)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, N-(2-(5-carbamoylpyridin-2-yloxy)ethyl)-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide (0.24 mmol) was reacted with boron tribromide to afford the desired product (28

mg, 28% yield) as a light yellow solid: ^{1}H NMR (300 MHz, CD_3OD) delta 8.69–8.68 (m, 1H), 8.12–8.09 (m, 1H), 7.74–7.69 (m, 2H), 7.49 (d, J = 5.1 Hz, 1H), 7.15–7.13 (m, 1H), 6.98 (d, J = 8.7 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 4.64 (t, J = 5.1 Hz, 2H), 3.93 (t, J = 5.1 Hz, 2H); ESI MS m/z 424 $[C_{20}H_{17}N_5O_4S + H]^+$; HPLC 98.9% (AUC), t_R = 11.01 min.

Example 50

7-Hydroxy-2-(thiophen-2-yl)-N-[2-(5-(trifluoromethyl)pyridin-2-yloxy)ethyl]-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, 7-methoxy-2-(thiophen-2-yl)-N-(2-(5-(trifluoromethyl)pyridin-2-yloxy)ethyl)-1H-benzo[d]imidazole-4-carboxamide (0.39 mmol) was reacted with boron tribromide to obtain the desired product (33 mg, 19% yield over 2 steps) as a white solid: ^{1}H NMR (300 MHz, CD_3OD) delta 8.42 (s, 1H), 7.96–7.87 (m, 2H), 7.80–7.72 (m, 2H), 7.26–7.23 (m, 1H), 7.01 (d, J = 9.0 Hz, 1H), 6.77 (d, J = 8.4 Hz, 1H), 4.67 (t, J = 5.1 Hz, 2H), 3.92 (t, J = 5.1 Hz, 2H); ESI MS m/z 449 $[C_{20}H_{15}F_3N_4O_3S + H]^+$; HPLC >99% (AUC), t_R = 14.71 min.

Example 51

Methyl 3-(1-tosyl-1H-imidazol-2-yl)acrylate



To a suspension of 1-tosyl-1H-imidazole-2-carbaldehyde (1.54 g, 6.2 mmol) in THF (75 mL) was added methyl(triphenylphosphoranylidene) acetate (2.46 g, 7.4 mmol) and the reaction mixture was heated at 75 degrees for 18 h. The reaction mixture was cooled, diluted with satd. aq $NaHCO_3$, extracted with ethyl acetate (100 mL), dried over Na_2SO_4, and purified by column chromatography (silica, 0-50% ethyl acetate/heptane) to afford the desired product (1.43 g, 76 % yield) as a clear oil: ESI MS m/z 307 $[C_{14}H_{14}N_2O_4S + H]^+$.

Example 52

Methyl 3-(1-tosyl-1H-imidazol-2-yl)propanoate



To a solution of methyl 3-(1-tosyl-1H-imidazol-2-yl)acrylate (1.43 g, 4.67 mmol) in MeOH (50 mL) was added cat. 10 wt % Pd/C (200 mg) and the reaction mixture was stirred under an atmosphere of hydrogen gas (1 atm) at room temperature for 18 h. The reaction mixture was filtered through diatomaceous earth, washed with MeOH, and concentrated to afford the desired product (1.35 g, 94 % yield) as a waxy solid: ESI MS m/z 309 $[C_{14}H_{16}N_2O_4S + H]^+$.

Example 53

Synthesis of 3-(1-Tosyl-1H-imidazol-2-yl)propan-1-ol



To a solution of methyl 3-(1-tosyl-1H-imidazol-2-yl)propanoate (1.35 g, 4.39 mmol) in THF (50 mL) at 0 degree was added DIBAL (11.8 mL, 11.8 mmol, 1.0 M) and the reaction mixture was stirred for1.5 h. The reaction mixture was warmed to room temperature over 2 h, concentrated, and purified by column chromatography (silica gel, 0-75% ethyl acetate/heptane) to afford the desired product (492 mg, 40 % yield) as a white solid: ESI MS m/z 281 $[C_{13}H_{16}N_2O_3S + H]^+$.

Example 54

2-[3-(1-Tosyl-1H-imidazol-2-yl)propyl]isoindoline-1,3-dione



A solution of 3-(1-Tosyl-1H-imidazol-2-yl)propan-1-ol (492 mg, 1.75 mmol), triphenylphosphine (636 mg, 2.63 mmol), and phthalimide (386 mg, 2.63 mmol) in THF (20 mL) was cooled to 0 degree and diisopropyl azodicarboxylate (532 mg, 2.63 mmol) was added and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was diluted with ethyl acetate (75 mL), washed with water (30 mL) and brine (30 mL), dried over Na_2SO_4, and purified by column chromatography (silica gel, 0-75% ethyl acetate/heptane) to afford the desired product (698 mg, 97 % yield) as a white foam: ESI MS m/z 410 $[C_{21}H_{19}N_3O_4S + H]^+$.

Example 55

3-(1H-Imidazol-2-yl)propan-1-amine



To a suspension of 2-[3-(1-tosyl-1H-imidazol-2-yl)propyl]isoindoline-1,3-dione (698 mg, 1.70 mmol) in EtOH (25 mL) was added hydrazine hydrate (1.9 mL, 34 mmol) and the reaction mixture was heated at reflux for 3 h. The reaction mixture was cooled and the resulting solids were filtered and washed with EtOH. The filtrate was concentrated and the crude product was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to afford the desired product (330 mg, crude) as a clear oil: ^{1}H NMR (300 MHz, CD_3OD) delta 6.90 (s, 2H), 2.82–2.65 (m, 4H), 1.86 (p, J = 7.2 Hz, 2H).

Example 56

N-[3-(1H-Imidazol-2-yl)propyl]-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide.



Following General Procedure B, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.15 g, 0.56 mmol) was reacted with 3-(1H-Imidazol-2-yl)propan-1-amine (0.14 g, 1.2 mmol) to afford the desired product (56 mg crude) as a tan solid: ESI MS m/z 382 $[C_{19}H_{19}N_5O_2S + H]^+$.

Example 57

N-3-(1H-Imidazol-2-yl)propyl)-]7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, N-[3-(1H-Imidazol-2-yl)propyl]-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide (0.15 mmol) was reacted with boron tribromide to afford the desired product (20 mg, 37% yield) as a light brown solid: ^{1}H NMR (300 MHz, DMSO-d_6) delta 13.45 (s, 1H), 11.86 (s, 1H), 10.81 (s, 1H), 9.63 (s, 1H), 8.07 (s, 1H), 7.77–7.68 (m, 2H), 7.25–7.22 (m, 1H), 6.88 (s, 2H), 6.73 (d, J = 8.1 Hz, 1H,), 3.47–3.45 (m, 2H), 2.82–2.73 (m, 2H), 1.97 (p, J = 7.2 Hz, 2H); ESI MS m/z 368 $[C_{18}H_{17}N_5O_2S + H]^+$; HPLC >99% (AUC), t_R = 9.21 min.

Example 58

tert-Butyl 3-oxopropylcarbamate



To a solution of tert-butyl 3-hydroxypropylcarbamate (0.50 g, 2.8 mmol) in CH_2Cl_2 (30 mL) was added Dess-Martin periodinane (1.3 g, 3.1 mmol) and pyridine (450 mg, 5.7 mmol) and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was quenched by the addition of satd. aq $NaHCO_3$ (20 mL) and solid $Na_2S_2O_3$ (1.0 g). The layers were separated and the aqueous layer was extracted with diethyl ether (25 mL). The combined organic layers were dried over Na_2SO_4, concentrated, and purified by column chromatography (silica gel, 0-75% ethyl acetate/heptane) to afford the desired product (360 mg, 73 % yield) as an oil: ^1H NMR (300 MHz, $CDCl_3$) delta 9.83 (s, 1H), 4.91 (s, 1H), 3.44 (q, J = 5.9 Hz, 2H), 2.73 (t, J = 5.9 Hz, 2H), 1.45 (s, 9H).

Example 59

tert-Butyl 2-(4,5-dihydro-1H-imidazol-2-yl)ethylcarbamate



To a solution of tert-Butyl 3-oxopropylcarbamate (360 mg, 2.09 mmol) in t-BuOH (20 mL) was added ethylenediamine (138 mg, 2.3 mmol) and the reaction mixture was stirred at room temperature for 18 h. Potassium carbonate (867 mg, 6.27 mmol) and iodine (690 mg, 2.72 mmol) were added and the reaction mixture was heated at 70 degrees for 2 h. The reaction mixture was quenched by the addition of satd. aq $Na_2S_2O_3$ (20 mL) and the pH was adjusted to 12 with 1 M NaOH. The reaction mixture was extracted with 3:1 $CHCl_3$/IPA (50 mL) and concentrated to afford the desired product (370 mg, 83% yield) as an orange oil: ESI MS m/z 214 $[C_{10}H_{19}N_3O_2 + H]^+$.

Example 60

2-(1H-imidazol-2-yl)ethanamine



To a solution of *tert*-Butyl 2-(4,5-dihydro-1H-imidazol-2-yl)ethylcarbamate (370 mg, 1.73 mmol) in DMSO (5 mL) was added potassium carbonate (528 mg, 3.82 mmol) and iodobenzene diacetate (1.23 g, 3.82 mmol) and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was heated at 50 degrees for 3 h, cooled, diluted with water (25 mL) and extracted with 3:1 $CHCl_3$/i-propanol (50 mL). The organic layer was dried over Na_2SO_4,

concentrated, and the crude product was dissolved in CH_2Cl_2 (10 mL) followed by the addition of trifluoroacetic acid (2 mL) and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was concentrated and the crude residue was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to afford the desired product (140 mg) as a brown solid: ^{1}H NMR (300 MHz, CD_3OD) delta 6.95 (s, 2H), 3.04–2.91 (m, 2H), 2.87–2.76 (m, 2H).

Example 61

N-[2-(1H-Imidazol-2-yl)ethyl]-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



To a suspension of 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.34 g, 1.3 mmol) in toluene (15 mL) was added thionyl chloride (0.61 g, 5.2 mmol). After stirring at room temperature for 16 h, the reaction mixture was heated at 70 degrees for 2 h. The reaction mixture was cooled to room temperature and concentrated. The residue was suspended in THF (20 mL) followed by the addition of pyridine (98 mg, 2.6 mmol) and 2-(1H-imidazol-2-yl)ethanamine (140 mg) and the reaction mixture was heated at 70 degrees for 16 h. The reaction mixture was concentrated and the residue was diluted with water (20 mL) and extracted with ethyl acetate (3x20 mL). The combined organic layers were washed with satd. aq $NaHCO_3$ (20 mL), concentrated, and purified by flash chromatography (silica, 0-15% methanol/dichloromethane) to afford the desired product: ESI MS m/z 368 $[C_{18}H_{17}N_5O_2S + H]^+$.

Example 62

N-[2-(1H-Imidazol-2-yl)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, N-(2-(1H-imidazol-2-yl)ethyl)-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide from Example 59 was reacted with boron tribromide to afford the desired product (5 mg, 3%

yield) as a light brown solid: ^{1}H NMR (300 MHz, CD_3OD) delta 7.85–7.84 (m, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 5.1 Hz, 1H), 7.21–7.18 (m, 1H), 7.06 (s, 2H), 6.69 (d, J = 8.4 Hz, 1H), 3.90 (t, J = 6.6 Hz, 2H), 3.15 (d, J = 6.6 Hz, 1H); ESI MS m/z 354 $[C_{17}H_{15}N_5O_2S + H]^+$; HPLC 97.7% (AUC), t_R = 9.56 min.

Example 63

7-Methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxamide



Following General Procedure B, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxylic acid (150 mg, 0.55 mmol) was reacted with excess NH_4OH to afford the desired product (42 mg) as a brown solid: ESI MS m/z 274 $[C_{13}H_{11}N_3O_2S + H]^+$.

Example 64

N-[2-(1H-Imidazol-5-yl)ethyl]-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxamide



Following General Procedure B, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxylic acid (150 mg, 0.55 mmol) was reacted with histamine (0.14 g, 1.1 mmol) to afford the desired product (92 mg) as a brown solid: ESI MS m/z 368 $[C_{18}H_{17}N_5O_2S + H]^+$.

Example 65

7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxamide



Following General Procedure C, 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxamide (40 mg) was reacted with boron tribromide to afford the desired product (13 mg, 32% yield) as an off-white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.83–7.82 (m, 1H), 7.65–7.63 (m, 1H), 7.61 (s, 1H), 7.22–7.20 (m, 1H), 7.18 (s, 1H); ESI MS m/z 260 $[C_{12}H_9N_3O_2S + H]^+$; HPLC >99% (AUC), t_R = 9.32 min.

Example 66

N-[2-(1H-Imidazol-5-yl)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxamide



Following General Procedure C, N-[2-(1H-imidazol-5-yl)ethyl]-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxamide was reacted with boron tribromide to afford the desired product (12 mg, 14% yield) as a light yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.82 (s, 1H), 7.69 (s, 1H), 7.64–7.63 (m, 1H), 7.53 (s, 1H), 7.21–7.20 (m, 1H), 7.10 (s, 1H), 6.93 (s, 1H), 3.64 (t, J = 7.0 Hz, 2H), 2.93 (t, J = 7.0 Hz, 2H); ESI MS m/z 354 $[C_{17}H_{15}N_5O_2S + H]^+$; HPLC 98.9% (AUC), t_R = 7.57 min.

Example 67

7-Hydroxy-N-[2-(5-nitropyridin-2-ylamino)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



To a suspension of 7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.65 g, 2.5 mmol) in dichloromethane (25 mL) was added N^1-(5-nitropyridin-2-yl)ethane-1,2-diamine (0.50 g, 2.75 mmol), EDC (0.58 g, 3.0 mmol), HOBt (0.40 g, 3.0 mmol), and DIPEA (0.97 g, 7.5 mmol) and the reaction mixture was stirred at room temperature for 16 h. Analysis by LC-MS indicated that the reaction was not complete, therefore, the dichloromethane was removed under reduced pressure, the residue was dissolved in DMF (5 mL), and the reaction mixture was heated at 50 degrees for 16 h. The reaction mixture was cooled, concentrated under reduced pressure, and triturated with water (20 mL) to afford the desired product (0.45 g, 42% yield) as a yellow-brown solid: ESI MS m/z 425 $[C_{19}H_{16}N_6O_4S + H]^+$. This intermediate was used without further purification or characterization.

Example 68

N-[2-(5-Aminopyridin-2-ylamino)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide Hydrochloride



To a solution of 7-hydroxy-N-(2-(5-nitropyridin-2-ylamino)ethyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide (0.22 g, 0.52 mmol) in ethanol (5 mL) and 6 N HCl (5 mL) was added iron powder (0.12 g, 2.1 mmol) and the reaction mixture was heated at reflux for 4 h. The reaction mixture was cooled to room temperature and concentrated to provide the desired product which was immediately carried forward without further purification or characterization: ESI MS m/z 395 $[C_{19}H_{18}N_6O_2S + H]^+$.

Example 69

7-Hydroxy-N-{2-[5-(methylsulfonamido)pyridin-2-ylamino]ethyl}-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



To a solution of crude N-(2-(5-aminopyridin-2-ylamino)ethyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide hydrochloride (0.29 g, 0.68 mmol) in DMF (5 mL) was added DIPEA (0.44 g, 3.4 mmol) and methanesulfonyl chloride (0.085 g, 0.75 mmol) and the reaction mixture was stirred for 16 h at room temperature. The reaction mixture was concentrated under reduced pressure and purified by flash chromatography (silica, 0-20% methanol/dichloromethane) to afford the desired product (59 mg, 18% yield) as a white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.87 (d, J = 2.5 Hz, 1H), 7.82–7.78 (m, 2H), 7.59 (d, J = 4.5 Hz, 1H), 7.37 (dd, J = 8.5, 2.5 Hz, 1H), 7.17 (s, 1H), 6.69 (d, J = 8.5 Hz, 1H), 6.62 (d, J = 8.5 Hz, 1H), 3.78 (bs, 2H), 3.64 (bs, 2H), 2.83 (s, 3H); ESI MS m/z 473 $[C_{20}H_{20}N_6O_4S_2 + H]^+$; HPLC >99% (AUC), t_R = 10.42 min.

Example 70

N-[2-(5-Acetamidopyridin-2-ylamino)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



To a solution of N-(2-(5-aminopyridin-2-ylamino)ethyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide hydrochloride (0.22 g, 0.52 mmol) in DMF (5 mL) was added DIPEA (0.34 g, 2.6 mmol) and acetyl chloride (0.045 g, 0.57 mmol) and the reaction mixture was stirred for 16 h at room temperature. The reaction mixture was concentrated under reduced pressure and purified by flash chromatography (silica, 0-20% methanol/dichloromethane) to afford the desired product (55 mg, 24% yield) as an off-white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 8.42 (s, 1H), 7.85 (d, J = 3.5 Hz, 1H), 7.80 (d, J = 6.5 Hz, 1H), 7.69 (dd, J = 9.5, 2.0 Hz, 1H), 7.61 (d, J = 4.5 Hz, 1H), 7.21 (d, J = 4.0 Hz, 1H), 7.07 (d, J = 9.0 Hz, 1H), 6.71 (d, J = 8.5 Hz, 1H), 3.82–3.81 (m, 2H), 3.71–3.68 (m, 2H) 2.12 (s, 3H); ESI MS m/z 437 $[C_{21}H_{20}N_6O_3S + H]^+$; HPLC 96.0% (AUC), t_R = 9.97 min.

Example 71

(S)-2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(1H-imidazol-5-yl)propanoic Acid



A solution of (S)-methyl 2-(7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido)-3-(1H-imidazol-5-yl) propanoate (30 mg, 0.062 mmol) in 3 M NaOH (10 ml) was heated at 80 degrees for 4 h. The reaction mixture was cooled to room temperature and acidified to pH 5 with 3 M HCl. The resulting precipitate was filtered and the crude solid was purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA). The desired product was obtained as the trifluoroacetic acid salt which was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to afford the desired product (9.1 mg, 31% yield) as a yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 8.22 (s, 1H), 7.86 (d, J = 2.9 Hz, 1H), 7.70 (d, J = 8.2 Hz, 1H), 7.58 (d, J = 4.7 Hz, 1H), 7.22 (s, 1H), 7.15 (t, J = 4.2 Hz, 1H), 6.66 (d, J = 8.3 Hz, 1H), 3.38–3.33 (m, 2H); ESI MS m/z 398 $[C_{18}H_{15}N_5O_4S + H]^+$; HPLC 97.8% (AUC), t_R = 7.07 min.

Example 72

(S)-2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(1H-indol-3-yl)propanoic Acid



A solution of (S)-methyl 2-(7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido)-3-(1H-indol-3-yl) propanoate (40 mg, 0.060 mmol) in 3 M NaOH (10 ml) was heated at 80 degrees for 4 h. The reaction mixture was cooled to room temperature and acidified to pH 5 with 3 M HCl. The resulting precipitate was filtered and the crude solid was purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA). The desired product was obtained as the trifluoroacetic acid salt which was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to afford the desired product (25 mg, 64% yield) as a yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.76 (bs, 1H), 7.63 (bs, 2H), 7.49 (bs, 1H), 7.29 (bs, 1H), 7.21 (d, J = 4.2 Hz, 1H), 7.10 (bs, 1H), 6.99 (t, J = 7.5 Hz, 1H), 6.89 (d, J = 3.2 Hz, 1H), 6.56 (bs, 1H), 3.51 (bs, 1H), 3.51–3.38 (m, 1H); ESI MS m/z 447 $[C_{23}H_{18}N_4O_4S + H]^+$; HPLC 97.8% (AUC), t_R = 7.07 min.

Example 73

7-Hydroxy-N-[2-(4-nitrophenoxy)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide.



Following General Procedure A, 7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.25 g, 0.95 mmol) was reacted with 2-(4-nitrophenoxy)ethanamine (0.34 g, 1.9 mmol) to obtain the desired product (230 mg, 57%) as a yellow solid: ^{1}H NMR (500 MHz, DMSO-d_6) delta 13.44 (s, 1H), 10.83 (s, 1H), 9.85 (s, 1H), 8.23–8.20 (m, 2H), 8.03–8.02 (m, 1H), 7.75–7.71 (m, 2 H), 7.28–7.21 (m, 3H), 6.73 (d, J = 8.3 Hz, 1H), 4.35 (t, J = 10.0 Hz, 2H), 3.88 (t, J = 11.0 Hz, 2H); ESI MS m/z 425 $[C_{20}H_{16}N_4O_5S + H]^+$; HPLC 98.2% (AUC), t_R = 13.25 min.

Example 74

7-Hydroxy-N-{2-[4-(4-methylphenylsulfonamido)phenoxy]ethyl}-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



To a solution of 7-hydroxy-N-(2-(4-nitrophenoxy)ethyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide (0.20 g, 0.48 mmol) in EtOH (20 mL) was added iron filings (160 mg, 2.8 mmol) and 6 N HCl (15 mL, 90 mmol) and the reaction mixture was heated at reflux for 16 h. The reaction mixture was cooled to room temperature and concentrated. The resulting crude aniline was dissolved in DMF (5 mL) followed by the addition of p-toluenesulfonyl chloride (0.13 g, 0.72 mmol) and DIPEA (0.16 g, 1.3 mmol). The reaction mixture was stirred at room temperature for 16 h, quenched with satd. aq NaCl (50 mL), and extracted with ethyl acetate (2x50 mL). The combined organic layers were washed with satd. aq NaCl (50 mL), dried over Na_2SO_4, concentrated, and purified by preparatory HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA) to afford the desired product (15 mg, 6% yield) as a light yellow solid: ^{1}H NMR (300 MHz, CD_3OD) delta 7.81–7.76 (m, 2H), 7.54–7.51 (m, 3H), 7.21 (d, J = 8.0 Hz, 2H), 7.13 (t, J = 8.3 Hz, 1H), 6.92 (q, J = 8.8 Hz, 4H), 6.69 (d, J = 8.3 Hz, 1H), 4.18 (t, J = 5.0 Hz, 2H), 3.86 (t, J = 5.1 Hz, 2H), 2.32 (s, 3H); ESI MS m/z 549 $[C_{27}H_{24}N_4O_5S_2 + H]^+$; HPLC > 99% (AUC), t_R = 14.76 min.

Wherein, NHTs means p-toluenesulfonamido.

Example 75

N-[3-(1H-Imidazol-1-yl)propyl]-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 7-Methoxy-2-(thiophen-2-yl)-1*H*-benzo[d]imidazole-4-carboxylic Acid (150 mg, 0.55 mmol) was reacted with 3-(1H-imidazol-1-yl)propan-1-amine (0.14 g, 1.1 mmol) to afford the desired product (117 mg) as a light yellow oil: ESI MS m/z 382 $[C_{19}H_{19}N_5O_2S + H]^+$.

Example 76

N-[3-(1H-Imidazol-1-yl)propyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, N-(3-(1H-imidazol-1-yl)propyl)-7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide (115 mg) was reacted with boron tribromide to afford the desired product (41 mg, 20% yield) as a light yellow-brown solid: ^{1}H NMR (300 MHz, CD_3OD) delta 7.89–7.88 (m, 1H), 7.80–7.77 (m, 1H), 7.64–7.63 (m, 1H), 7.24–7.20 (m, 1H), 6.99 (s, 1H), 6.71 (d, 1H, J = 8.3 Hz), 4.29–4.25 (m, 2H), 3.53–3.49 (m, 2H), 2.24–2.19 (m, 2H); ESI MS m/z 368 $[C_{18}H_{17}N_5O_2S + H]^+$; HPLC 97.3% (AUC), t_R = 9.69 min.

Example 77

2-(Furan-2-yl)-7-hydroxy-N-phenethyl-1H-benzo[d]imidazole-4-carboxamide



To a solution of 2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.58 mmol) in DMF (5 mL) was added HATU (0.26 g, 0.69 mmol) 2-phenylethanamine (0.14 g, 1.2 mmol), and DIPEA (0.22 g, 1.7 mmol) and the reaction mixture was stirred at 80 degrees for 16 h. The reaction mixture was cooled to room temperature, diluted with satd. aq $NaHCO_3$ (50 mL), and extracted with ethyl acetate (3x30 mL). The combined organic layers were washed with satd. aq NaCl (50 mL), concentrated, and purified by flash chromatography (silica, 0-15% methanol/dichloromethane) to afford the desired product (15 mg, 6.7 % yield) as a light yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.80 (d, J = 4.3 Hz, 1H), 7.75 (s, 1H), 7.35 (d, J = 3.7 Hz, 1H), 7.27 (m, J = 7.5 Hz, 2H), 7.19 (t, J = 7.6 Hz, 1H), 7.08 (d, J = 3.0 Hz, 1H), 6.70–6.66 (m, 2H), 3.79 (t, J = 7.0 Hz, 2H), 3.00 (t, J = 7.0 Hz, 2H); ESI MS m/z 348 $[C_{20}H_{17}N_3O_3 + H]^+$; HPLC 98.6% (AUC), t_R = 13.12 min.

Example 78

Synthesis of 2-(Furan-2-yl)-7-hydroxy-N-phenyl-1H-benzo[d]imidazole-4-carboxamide



To a solution of 2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.58 mmol) in DMF (5 mL) was added HATU (0.26 g, 0.69 mmol,) aniline (0.11 g, 1.2 mmol), and DIPEA (0.22 g, 1.7 mmol) and the reaction mixture was stirred at 80 degrees for 16 h. The reaction mixture was cooled to room temperature, diluted with satd. aq $NaHCO_3$ (50 mL), and extracted with ethyl acetate (3x30 mL). The combined organic layers were washed with satd. aq NaCl (50 mL), concentrated, and purified by flash chromatography (silica, 0-15% methanol/dichloromethane) to afford the desired product (21 mg, 10 % yield) as a light yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.90 (d, J = 8.6 Hz, 1H), 7.82 (s, 1 H), 7.81 (d, J = 5.8 Hz, 2 H), 7.40 (t, J =14.9 Hz, 2H), 7.33 (d, J = 3.3 Hz, 1H), 7.13 (t, J = 14.6 Hz, 1H), 6.76 (d, J = 8.2 Hz, 1H), 6.71 (s, 1H); ESI MS m/z 320 $[C_{18}H_{13}N_3O_3 + H]^+$; HPLC 92.7% (AUC), t_R = 13.27 min.

Example 79

7-Hydroxy-N-[3-(5-oxo-4,5-dihydro-1H-pyrazol-4-yl)propyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



To a solution of 2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.58 mmol) in DMF (5 mL) was added HATU (0.26 g, 0.69 mmol) 4-(3-aminopropyl)-1H-pyrazol-5(4H)-one (0.17 g, 1.2 mmol) and DIPEA (0.22 g, 1.7 mmol) and the reaction mixture was stirred at 80 degrees for 16 h. The reaction mixture was cooled to room temperature, diluted with satd. aq $NaHCO_3$ (50 mL), and extracted with ethyl acetate (3x30 mL). The combined organic layers were washed with satd. aq NaCl (50 mL), concentrated, and purified by flash chromatography (silica, 0-15% methanol/dichloromethane) to afford the desired product (15 mg, 5% yield) as a light yellow solid: ^{1}H NMR (300 MHz, CD_3OD) delta 7.76–7.59 (m, 2H), 7.35(s, 1H), 7.27 (d, J = 3.4 Hz, 1H), 6.71–6.66 (m, 2H) 3. 54 (t, J = 15.7 Hz, 2H), 2.57 (t, J = 14.5 Hz, 2H), 1.96–1.92 (m, 2H); ESI MS m/z 368 $[C_{18}H_{17}N_5O_4 + H]^+$; HPLC >95.9% (AUC), t_R = 9.59 min.

Example 80

N-(3,4-Dihydroxyphenethyl)-2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxamide



To a solution of 2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic acid (150 mg, 0.58 mmol) in DMF (5 mL) was added HATU (0.26 g, 0.69 mmol), 4-(2-aminoethyl)benzene-1,2-diol (0.18 g, 1.2 mmol), and DIPEA (0.22 g, 1.7 mmol) and the reaction mixture was stirred at 80 degrees for 16 h. The reaction mixture was cooled to room temperature, diluted with satd. aq $NaHCO_3$ (50 mL), and extracted with ethyl acetate (3x30 mL). The combined organic layers were washed with satd. aq NaCl (50 mL), concentrated, and purified by flash chromatography (silica, 0-15% methanol/dichloromethane) to afford the desired product (20 mg, 6% yield) as an off-white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.80 (d, J = 8.1 Hz, 1H), 7.74 (s, 1H), 7.08 (s, 1H), 6.76 (s, 1H), 6.68–6.66 (m, 4H), 3.74 (t, J = 6.5 Hz, 2H), 2.84 (t, J = 6.6 Hz, 2H) ; ESI MS m/z 380 $[C_{20}H_{17}N_3O_5 + H]^+$.

Example 81

2-(Furan-2-yl)-7-methoxy-N-(2-(1-methyl-1H-pyrrol-2-yl)ethyl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 2-(furan-2-yl)-7-methoxy-1H-benzo[d]imidazole-4-carboxylic acid (0.15 g, 0.57 mmol) was reacted with 2-(1-methyl-1H-pyrrol-2-yl)ethanamine (0.14 g, 1.2 mmol) to afford the desired product (135 mg) as a light yellow oil: ESI MS m/z 365 $[C_{20}H_{20}N_4O_3 + H]^+$.

Example 82

N-[2-(3,5-Dimethylisoxazol-4-yl)ethyl]-2-(furan-2-yl)-7-methoxy-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 2-(furan-2-yl)-7-methoxy-1H-benzo[d]imidazole-4-carboxylic acid (0.15 g, 0.57 mmol) was reacted with 2-(3,5-dimethylisoxazol-4-yl)ethanamine (0.17 g, 1.2 mmol) to afford the desired product (230 mg) as a light yellow oil: ESI MS m/z 381 $[C_{20}H_{20}N_4O_4+ H]^+$.

Example 83

2-(Furan-2-yl)-7-methoxy-N-(thiazol-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure B, 2-(furan-2-yl)-7-methoxy-1H-benzo[d]imidazole-4-carboxylic acid (17 mg, 0.64 mmol) was reacted with thiazol-2-amine (0.12 g, 1.2 mmol) to afford the desired product (194 mg) as a brown solid: ESI MS m/z 341 $[C_{16}H_{12}N_4O_3S + H]^+$.

Example 84

2-(Furan-2-yl)-7-hydroxy-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, 2-(Furan-2-yl)-7-methoxy-N-(2-(1-methyl-1H-pyrrol-2-yl)ethyl)-1H-benzo[d]imidazole-4-carboxamide (135 mg) was reacted with boron tribromide to afford the desired product (18 mg, 7% yield) as a light yellow-brown solid: ^{1}H NMR (300 MHz, CD_3OD) delta 7.81 (d, J = 8.3

Hz, 1H), 7.75 (s, 1H), 7.19 (d, J = 3.3 Hz, 1H,), 6.71–6.66 (m, 2H), 6.56 (t, J = 4.3 Hz, 1H), 6.02–5.97 (m, 2H), 3.77 (t, J = 6.9 Hz, 2H), 3.60 (s, 3H), 2.96, (t, J = 6.8 Hz, 2H) (ESI MS m/z 351 $[C_{19}H_{18}N_4O_3 + H]^+$; HPLC 96.7% (AUC), t_R = 12.53 min.

Example 85

N-(2-(3,5-dimethylisoxazol-4-yl)ethyl)-2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, N-[2-(3,5-Dimethylisoxazol-4-yl)ethyl]-2-(furan-2-yl)-7-methoxy-1H-benzo[d]imidazole-4-carboxamide (230 mg) was reacted with boron tribromide to afford the desired product (18 mg, 7% yield) as an off-white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.77–7.75 (m, 2H), 7.31 (bs, 1H), 6.75–6.69 (m, 2H) 3.62 (t, J = 12.6 Hz, 2H), 2.74 (t, J =11.8 Hz, 2H), 2.27 (s, 3H), 2.24 (s, 3H) ESI MS m/z 367 $[C_{19}H_{18}N_4O_4 + H]^+$; HPLC 96.8% (AUC), t_R = 11.65 min.

Example 86

2-(Furan-2-yl)-7-hydroxy-N-(thiazol-2-yl)-1H-benzo[d]imidazole-4-carboxamide



Following General Procedure C, 2-(Furan-2-yl)-7-methoxy-N-(thiazol-2-yl)-1H-benzo[d]imidazole-4-carboxamide (194 mg) was reacted with boron tribromide to afford the desired product (25 mg, 12% yield) as a light yellow solid: ^{1}H NMR (300 MHz, CD_3OD) delta 7.95 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 3.6 Hz, 1H), 7.53 (d, J = 3.6 Hz, 1H), 7.19 (d, J = 3.6 Hz, 1H), 6.80 (d, J = 8.4 Hz, 1H), 6.73–6.71 (m, 1H); ESI MS m/z 327 $[C_{15}H_{10}N_4O_3S + H]^+$; HPLC >99% (AUC), t_R = 12.88 min.

Example 87

2-(Furan-2-yl)-7-hydroxy-N-[2-(5-nitropyridin-2-ylamino)ethyl]-1H-benzo[d]imidazole-4-carboxamide



To a suspension of 2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic acid (0.50 g, 2.0 mmol) in DMF (4 mL) was added N^1-(5-nitropyridin-2-yl)ethane-1,2-diamine (0.41 g, 2.2 mmol), HATU (0.93 g, 2.5 mmol), DMAP (0.025 g, 0.20 mmol), and diisopropylethylamine (0.79 g, 6.2 mmol) and the reaction mixture stirred for 16 h at 50 degrees. The reaction mixture was quenched by the addition of water (25 mL) and extracted with dichloromethane (3x50 mL). The combined organic layers were dried over $NaSO_4$, filtered, and concentrated under reduced pressure. The crude residue was triturated in dichloromethane (10 mL) to afford the first batch of 50. The filtrate was concentrated and purified by flash chromatography (silica, 0-20% methanol/dichloromethane) and combined with the first batch to afford the desired product (0.30 g, 36% yield) as a yellow solid: ESI MS m/z 409 $[C_{19}H_{16}N_6O_5 + H]^+$.

Example 88

N-[2-(5-Aminopyridin-2-ylamino)ethyl]-2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxamide hydrochloride



To a solution of 2-(Furan-2-yl)-7-hydroxy-N-[2-(5-nitropyridin-2-ylamino)ethyl]-1H-benzo[d]imidazole-4-carboxamide (0.30 g, 0.73 mmol) in ethanol (7 mL) and 6 N HCl (7 mL) was added iron powder (0.20 g, 3.7 mmol) and the reaction mixture was heated at reflux for 4 h. The reaction mixture was concentrated under reduced pressure to afford the desired product which was used immediately in the next step without further purification: ESI MS m/z 379 $[C_{19}H_{18}N_6O_3 + H]^+$.

Example 89

2-(Furan-2-yl)-7-hydroxy-N-{2-[5-(4-methylphenylsulfonamido)pyridin-2-ylamino]ethyl}-1H-benzo[d]imidazole-4-carboxamide.



To a solution of N-[2-(5-Aminopyridin-2-ylamino)ethyl]-2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxamide hydrochloride (0.73 mmol) in DMF (7 mL) was added DIPEA (0.47 g, 3.7 mmol) and p-toluenesulfonyl chloride (0.15 g, 0.80 mmol) and the reaction mixture was stirred for 16 h at room temperature. The reaction mixture was quenched by the addition of water (25 mL) and the black solid was removed by vacuum filtration. The filtrate was concentrated under reduced pressure and the crude residue was triturated in methanol and filtered. The filtrate was concentrated and purified by flash chromatography (silica, 0-20% methanol/dichloromethane) to afford crude product. The crude product was purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA). The desired product was obtained as the trifluoroacetic acid salt which was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to afford the desired product (42 mg, 11% yield) as a white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.74 (bs, 1H), 7.51–7.49 (m, 3H), 7.25–7.23 (m, 2H), 7.15 (dd, J = 9.0, 2.5 Hz, 2H), 6.69 (d, J = 8.5 Hz, 1H), 6.66 (d, J = 1.5 Hz, 2H), 6.49 (d, J = 9.0 Hz, 1H), 3.71 (bs, 2H), 3.54 (bs, 2H), 2.35 (s, 3H); ESI MS m/z 533 $[C_{26}H_{24}N_6O_5S + H]^+$; HPLC >99% (AUC), t_R = 11.73 min.

Example 90

N-[2-(1H-Imidazol-5-yl)ethyl]-7-fluoro-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide



To a solution of 7-fluoro-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (100 mg, 0.38 mmol) in DMF (3 mL) was added HATU (160 mg, 0.41 mmol), DIPEA (0.35 mL, 1.9 mmol), and 2-(1H-imidazol-4-yl)ethanamine (100 mg, 0.57 mmol) and the reaction mixture stirred at 60 degrees for 5 h. The reaction mixture was cooled to room temperature, concentrated, and the crude residue was purified by column chromatography (silica, 5:95 methanol/methylene chloride) to afford the desired product (110 mg, 43%) as an off-white solid: ^{1}H NMR (500 MHz, DMSO) delta 9.42 (bs, 1H), 8.10 (s, 1H), 7.82 (d, J = 4.6 Hz, 1H), 7.78 (s, 1H), 7.57 (s, 1H), 7.26 (t, J = 8.40 Hz, 1H), 7.15 (t, J = 9.3 Hz, 1H), 6.91 (s, 1H), 3.67–3.65 (m, 2H), 2.84 (t, J = 6.9 Hz, 2H); ESI MS m/z 356 $[C_{17}H_{14}FN_5OS + H]^+$; HPLC 98.8% (AUC), t_R = 9.41 min.

Example 91

2-Cyclopropyl-N-(4-hydroxyphenyl)-4-methoxy-1H-benzo[d]imidazole-7-carboxamide



Following General procedure A, 2-cyclopropyl-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic acid (40 mg, 0.18 mmol) was reacted with 4-aminophenol (31 mg, 0.28 mmol) to afford the desired product1 (18 mg, 32% yield) as a brown yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.76 (d, J = 8.5 Hz, 1H), 7.51 (d, J = 8.5 Hz, 2H), 6.80 (m, 2H), 6.65 (d, J = 8.5 Hz, 1H), 2.21 (m, 1H), 1.23–1.18 (m, 4H); ESI MS m/z 310 $[C_{17}H_{15}N_3O_3 + H]^+$; HPLC >99% (AUC), t_R = 9.06 min.

Example 92

4-Hydroxy-N-(4-hydroxyphenethyl)-2-phenyl-1H-benzo[d]imidazole-7-carboxamide



Following General procedure A, 7-hydroxy-2-phenyl-1H-benzo[d]imidazole-4-carboxylic acid (63 mg, 0.25 mmol) was reacted 4-aminophenol (52 mg, 0.38 mmol) to afford the desired product (20 mg, 21% yield) as a light brown solid: ^{1}H NMR (500 MHz, DMSO-d_6) delta 13.30 (s, 1H), 10.71 (s, 1H), 9.69–9.67 (m, 1H), 9.20 (s, 1H), 8.13–8.12 (m, 2H), 7.73 (d, 8.5 Hz, 1H), 7.58–7.55 (m, 3H), 7.15 (d, J = 8.5 Hz, 2H), 6.74–6.71 (m, 3H), 3.72–3.69 (m, 2H), 3.32 (bs, 1H), 2.51–2.50 (m, 2H); ESI MS m/z 374 $[C_{22}H_{19}N_3O_3 + H]^+$; HPLC >99% (AUC), t_R = 11.91 min.

Example 93

N-(4-Aminophenethyl)-4-hydroxy-2-phenyl-1H-benzo[d]imidazole-7-carboxamide



Following General procedure A, 7-hydroxy-2-phenyl-1H-benzo[d]imidazole-4-carboxylic acid (63 mg, 0.25 mmol) was reacted with benzene-1,4-diamine (52 mg, 0.38 mmol) to afford the desired product (15 mg, 16% yield) as a light brown solid: ^{1}H NMR (500 MHz, DMSO-d_6) delta 13.28 1 (s, 1H), 10.70 (s, 1H), 9.68 (s, 1H), 8.16 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 6.0 Hz, 1H), 7.607.57 (m, 2H), 7.52 (d, J = 7.5 Hz, 1H), 7.02 (d, J = 6.0 Hz, 2H), 6.72 (d, J = 8.5 Hz, 1H), 6.54 (d, J = 8.5 Hz, 2H), 3.66 (d, J = 6.0 Hz, 2H), 2.78–2.75 (m, 2H); ESI MS m/z 373 $[C_{22}H_{20}N_4O_2 + H]^+$; HPLC 95.7% (AUC), t_R = 9.07 min.

Example 94

4-Hydroxy-N-phenethyl-2-phenyl-1H-benzo[d]imidazole-7-carboxamide



Following General procedure A, 7-hydroxy-2-phenyl-1H-benzo[d]imidazole-4-carboxylic acid (63 mg, 0.25 mmol) was reacted with 4-(2-aminoethyl)aniline (46 mg, 0.38 mmol) to afford the desired product (28 mg, 27% yield) as a white solid: ^{1}H NMR (500 MHz, DMSO-d_6) delta 13.30 (s, 1H), 10.71 (s, 1H), 9.70 (s, 1H), 8.12 (d, J = 5.5 Hz, 2H), 7.72 (d, J = 8.0 Hz, 1H), 7.56–7.52 (m, 3H), 7.37–7.22 (m, 5H), 6.72 (d, J = 8.0 Hz, 1H), 3.76 (d, J = 5.5 Hz, 2H), 2.96–2.93 (m, 2H); ESI MS m/z 358 $[C_{22}H_{19}N_3O_2 + H]^+$; HPLC >99% (AUC), t_R = 14.39 min.

Example 95

2-Cyclopentyl-4-hydroxy-N-(4-hydroxyphenethyl)-1H-benzo[d]imidazole-7-carboxamide



Following General procedure A, 2-cyclopentyl-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic acid (80 mg, 0.28 mmol) was reacted with 4-(2-aminoethyl)phenol (58 mg, 0.42 mmol) to afford

the desired product (28 mg, 27% yield) as a white solid: ^{1}H NMR (500 MHz, DMSO-d_6) delta 12.56c(s, 1H), 10.46 (s, 1H), 9.71 (s, 1H), 9.13 (s, 1H), 7. 61 (d, J = 8.5 Hz, 1H), 7.08 (d, J = 8.5 Hz, 2H), 6.67–6.62 (m, 3H), 3.59–3.31 (m, 2H), 3.25–3.23 (m, 1H), 2.51–2.49 (m, 2H), 2.05–2.01 (m, 2H), 1.85–1.66 (m, 6H); ESI MS m/z 366 $[C_{21}H_{23}N_3O_3 + H]^+$; HPLC >99% (AUC), t_R = 10.44 min.

Example 96

N-(4-Aminophenethyl)-2-cyclopentyl-4-hydroxy-1H-benzo[d]imidazole-7-carboxamide



Following General procedure A, 2-cyclopentyl-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic acid (80 mg, 0.28 mmol) was reacted with 4-(2-aminoethyl)aniline (58 mg, 0.42 mmol) to afford the desired product (25 mg, 25% yield) as an off-white solid: ^{1}H NMR (500 MHz, DMSO-d_6) delta 12.56 (s, 1H), 10.45 (s, 1H), 9.72–9.70 (m, 1H), 7. 61 (d, J = 8.5 Hz, 1H), 6.94 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 8.5 Hz, 1H), 6.49–6.47 (m, 2H), 4.83 (bs, 2H), 3.56–3.52 (m, 2H), 3.33–3.25 (m, 1H), 2.51–2.49 (m, 2H), 2.07–2.02 (m, 2H), 1.89–1.79 (m, 4H), 1.68–1.66 (m, 2H); ESI MS m/z 365 $[C_{21}H_{24}N_4O_2 + H]^+$; HPLC >99% (AUC), t_R = 7.97 min.

Example 97

2-Cyclopropyl-N-(2,3-dihydroxypropyl)-4-hydroxy-1H-benzo[d]imidazole-7-carboxamide



Following General procedure A, 2-cyclopropyl-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic acid (55 mg, 0.25 mmol) was reacted with 3-aminopropane-1,2-diol (33 mg, 0.38 mmol) to afford the desired product (23 mg, 32% yield) as a light brown-yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.69 (bs, 1H), 6.62–6.60 (m, 1H), 3.85–3.82 (m, 1H), 3.68 (bs, 1H), 3.60–3.59 (m, 2H), 3.51–3.47 (m, 1H), 2.15 (bs, 1H), 1.21–1.10 (m, 4H); ESI MS m/z 292 $[C_{14}H_{17}N_3O_4 + H]^+$; HPLC >99% (AUC), t_R = 7.55 min.

Example 98

2-Cyclopropyl-N-(2-(dimethylamino)ethyl)-4-hydroxy-1H-benzo[d]imidazole-7-carboxamide



Following General procedure A, 2-cyclopropyl-7-hydroxy-1H-benzo[d]imidazole-4-carboxylic acid (55 mg, 0.25 mmol) was reacted with N^1,N^1-dimethylethane-1,2-diamine (33 mg, 0.38 mmol) to afford the desired product (35 mg, 49% yield) as a light brown-yellow solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.66 (d, J = 8.5 Hz, 1H), 6.60 (d, J = 8.5 Hz, 1H), 3.65 (t, J = 6.5 Hz, 2H), 2.77 (t, J = 6.5 Hz, 2H), 2.46 (s, 6H), 2.17 (bs, 1H), 1.19–1.12 (m, 4H); ESI MS m/z 289 $[C_{15}H_{20}N_4O_2 + H]^+$; HPLC >99% (AUC), t_R = 6.47 min.

Example 99

2-Cyclopropyl-4-methoxy-N-(4-sulfamoylphenethyl)-1H-benzo[d]imidazole-7-carboxamide



Following General procedure B, 2-cyclopropyl-7-methoxy-1H-benzo[d]imidazole-4-carboxylic acid (80 mg, 0.34 mmol) was reacted with 4-(2-aminoethyl)benzenesulfonamide (103 mg, 0.52 mmol) to afford the desired product (66 mg, 46% yield) as a brown solid: ESI MS m/z 415 $[C_{20}H_{22}N_4O_4S + H]^+$.

Example 100

2-Cyclopropyl-N-(4-fluorophenethyl)-4-methoxy-1H-benzo[d]imidazole-7-carboxamide



Following General procedure B, 2-cyclopropyl-7-methoxy-1H-benzo[d]imidazole-4-carboxylic acid (80 mg, 0.34 mmol) was reacted with 2-(4-fluorophenyl)ethanamine (72 mg, 0.52 mmol) to afford the desired product (80mg, 66% yield) as a white solid: ESI MS m/z 354 [$C_{20}H_{20}FN_3O_2$ + H]$^+$.

Example 101

2-Cyclopropyl-4-hydroxy-N-(4-sulfamoylphenethyl)-1H-benzo[d]imidazole-7-carboxamide



Following General procedure C, 2-Cyclopropyl-4-methoxy-N-(4-sulfamoylphenethyl)-1H-benzo[d]imidazole-7-carboxamide (60 mg, 0.15 mmol) was reacted with boron tribromide to afford the desired product (15 mg, 26% yield) as a off-white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.84–7.82 (m, 2H), 7.69 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 8.0 Hz, 2H), 6.59 (d, J = 8.0 Hz, 1H), 3.81–3.79 (m, 2H), 3.06–3.03 (m, 2H), 2.08 (bs, 1H), 1.12–1.00 (m, 4H); ESI MS m/z 401 [$C_{19}H_{20}N_4O_4S$ + H]$^+$; HPLC 96.5% (AUC), t_R = 9.05 min.

Example 102

2-Cyclopropyl-N-(4-fluorophenethyl)-4-hydroxy-1H-benzo[d]imidazole-7-carboxamide



Following General procedure C, 2-Cyclopropyl-N-(4-fluorophenethyl)-4-methoxy-1H-benzo[d]imidazole-7-carboxamide (60 mg, 0.17 mmol) was reacted with boron tribromide to afford the desired product (15 mg, 26% yield) as a off-white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.69 (bs, 1H), 7.30–7.27 (m, 2H), 7.02–6.99 (m, 2H), 6.60 (d, J = 8.0 Hz, 1H), 3.72 (bs, 2H), 2.94–2.91 (m, 2H), 2.11 (bs, 1H), 1.00–1.00 (m, 4H); ESI MS m/z 340 $[C_{19}H_{18}FN_3O_2 + H]^+$; HPLC 98.9% (AUC), t_R = 11.49 min.

Example 103

tert-Butyl 2-cyclopropyl-7-methoxy-1H-benzo[d]imidazol-4-ylcarbamate and 1,3-bis(2-cyclopropyl-7-methoxy-1H-benzo[d]imidazol-4-yl)urea



To the solution of 2-cyclopropyl-7-methoxy-1H-benzo[d]imidazole-4-carboxylic acid (1.4 g, 6.0 mmol) in 1,4-dioxane (100 mL) was added t-butanol (4 mL), triethylamine (2.0 mL, 15 mmol), and DPPA (2.5 g, 9.0 mmol) and the reaction mixture was stirred at room temperature for 2 h. Additional t-butanol (4 mL) was added and the reaction mixture was heated at 100 degrees for 18 h. The reaction mixture was cooled to room temperature, concentrated, diluted with ice water (40 mL), and the mixture was extracted with EtOAc (3x60 mL). The combined organic layers were washed with 5% aq $NaHCO_3$ (50 mL), brine (50 mL), dried over Na_2SO_4, and concentrated to afford a mixture of products (1.4 g) as dark blue solid which was carried forward without further purification: ESI MS m/z 304 $[C_{16}H_{21}N_3O_3 + H]^+$ and ESI MS m/z 433 $[C_{23}H_{24}N_6O_3 + H]^+$.

Example 104

2-Cyclopropyl-7-methoxy-1H-benzo[d]imidazol-4-amine



To a solution of tert-butyl 2-cyclopropyl-7-methoxy-1H-benzo[d]imidazol-4-ylcarbamate and 1,3-bis(2-cyclopropyl-7-methoxy-1H-benzo[d]imidazol-4-yl)urea (1.4 g) in 1,4-dioxane (30 mL) was added a solution of KOH (1.3 g, 24 mmol) in water (5mL) and the reaction mixture was heated at reflux for 3 h. The reaction mixture was cooled to room temperature, concentrated, and diluted with ice water (30 mL). The pH of the mixture was adjusted to 7 using glacial acetic acid followed by extraction with EtOAc (3x80 mL). The combined organic layers were dried over Na_2SO_4 and concentrated. The crude residue was dissolved in CH_2Cl_2 (5 mL) and cooled to 0 degree followed by the addition of TFA (2 mL). The reaction mixture was stirred at room temperature for 2 h, concentrated, and diluted with ice water (20 mL). The pH of the mixture was adjusted to 7 using glacial acetic acid followed by extraction with EtOAc (3x60 mL). The combined organic layers were dried over Na_2SO_4, concentrated, and the residue was purified by flash chromatography (silica gel, 33-50 % EtOAc/Hexanes) to afford the desired product (0.88 g, 72% yield) as dark blue solid: ESI MS m/z 204 $[C_{11}H_{13}N_3O + H]^+$.

Example 105

N-(2-Cyclopropyl-7-methoxy-1H-benzo[d]imidazol-4-yl)-2-(4-methoxyphenyl)acetamide



To the solution of 2-cyclopropyl-7-methoxy-1H-benzo[d]imidazol-4-amine (50 mg, 0.24 mmol) in THF (5 mL) was added triethylamine (48 micro L, 0.36 mmol) and 2-(4-methoxyphenyl)acetyl chloride (44 mg, 0.24 mmol) and the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was diluted with EtOAc (20 mL) and washed with 5% aq $NaHCO_3$ (50 mL) and brine (50 mL). The layers were separated and the organic layer was dried over Na_2SO_4, concentrated, and the residue was purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA) to afford the desired product (60 mg, 71% yield) as dark purple-blue solid: ESI MS m/z 352 $[C_{20}H_{21}N_3O_3 + H]^+$.

Example 106

1-(2-Cyclopropyl-7-methoxy-1H-benzo[d]imidazol-4-yl)-3-(4-methoxyphenyl)urea



To the solution of 2-cyclopropyl-7-methoxy-1H-benzo[d]imidazol-4-amine (50 mg, 0.24 mmol) in THF (5 mL) was added triethylamine (48 micro L, 0.36 mmol) and 4-methoxyphenylcarbamic chloride (44 mg, 0.24 mmol) and the reaction mixture was stirred at room temperature for 30

min. The reaction mixture was diluted with EtOAc (20 mL) and washed with 5% aq $NaHCO_3$ (50 mL) and brine (50 mL). The layers were separated and the organic layer was dried over Na_2SO_4, concentrated, and the residue was purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA) to afford the desired product (66 mg, 78% yield) as dark purple-blue solid: ESI MS m/z 353 $[C_{19}H_{20}N_4O_3 + H]^+$.

Example 107

N-(2-cyclopropyl-7-hydroxy-1H-benzo[d]imidazol-4-yl)-2-(4-hydroxyphenyl)acetamide



To the solution of N-(2-cyclopropyl-7-methoxy-1H-benzo[d]imidazol-4-yl)-2-(4-methoxyphenyl)acetamide (45 mg, 0.13 mmol) in CH_2Cl_2 (15 mL) was added BBr_3 (2.1 mL, 1 M in CH_2Cl_2) and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was poured into ice water (15 mL) and the pH was adjusted to 6 using conc. NH_4OH. The reaction mixture was extracted with EtOAc (3x20 mL) and the combined organic layers were washed with 5% aq $NaHCO_3$ (50 mL) and brine (50 mL). The layers were separated and the organic layer was dried over Na_2SO_4, concentrated, and the residue was purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA) to afford the desired product (22 mg, 53% yield) as light purple-blue solid: ^1H NMR (500 MHz, CD_3OD) delta 7.28–7.20 (m, 3H), 6.77–6.75 (m, 2H), 6.50 (d, J = 8.5 Hz, 1H), 3.64 (s, 2H), 2.15 (bs, 1H), 1.13–1.11 (m, 4H); ESI MS m/z 324 $[C_{18}H_{17}N_3O_3 + H]^+$; HPLC 95.7% (AUC), t_R = 8.40 min.

Example 108

1-(2-Cyclopropyl-7-hydroxy-1H-benzo [d]imidazol-4-yl)-3- (4-hydroxyphenyl)urea



To the solution of 1-(2-cyclopropyl-7-methoxy-1H-benzo[d]imidazol-4-yl)-3-(4-methoxyphenyl)urea (50 mg, 0.13 mmol) in CH_2Cl_2 (15 mL) was added BBr_3 (2.13 mL, 1 M in CH_2Cl_2,) and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was poured into ice water (15

mL) and the pH was adjusted to 6 using conc. NH_4OH. The reaction mixture was extracted with EtOAc (3x20 mL) and the combined organic layers were washed with 5% $NaHCO_3$ (50 mL), brine (50 mL), dried over Na_2SO_4, concentrated, and the residue was purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA) to afford the desired product (19 mg, 42% yield) as a light blue solid: ^1H NMR (500 MHz, CD_3OD) delta 7.21 (d, J = 9.0 Hz, 2H), 7.05 (bs, 1H), 6.73 (d, J = 9.0 Hz, 2H), 6.52 (d, J = 8.0 Hz, 1H), 2.17–2.13 (m, 1H), 1.13–1.09 (m, 4H); ESI MS m/z 325 $[C_{17}H_{16}N_4O_3 + H]^+$; HPLC 95.6% (AUC), t_R = 8.99 min.

Example 109

N-[2-(1H-Imidazol-5-yl)ethyl]-7-(benzyloxy)-1H-indole-3-carboxamide



To a solution of 7-(benzyloxy)-1H-indole (1.0 g, 4.5 mmol) in DMF (10 mL) was added TFAA (2.0 g, 9.0 mmol) and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was quenched by the addition of water (50 mL) and extracted with EtOAc (3x30 mL). The combined organic layers were dried over Na_2SO_4, concentrated, and the crude residue was diluted in 6 N NaOH (15 mL) and ethanol (15 ml) and heated at reflux for 18 h. The reaction mixture was cooled to room temperature and acidified to pH 2 using 6 N HCl. The resulting solids were filtered and dried to obtain the crude acid (1.0 g) as an off-white solid. The crude acid intermediate (0.5 g) was dissolved in DMF (5 mL) followed by the addition of HATU (0.84 g, 2.2 mmol), DIPEA (1.2 mL, 6.6 mmol), histamine (0.50 g, 4.5 mmol) and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3x30 mL). The combined organic layers were dried over Na_2SO_4, concentrated, and the residue was triturated with CH_2Cl_2 (20 mL). The solids were filtered to afford the desired product (0.15 g, 19% for two steps): ^1H NMR (300 MHz, CD_3OD) delta 7.79 (s, 1H), 7.59–7.51 (m, 4H), 7.47–7.28 (m, 3H), 7.04 (t, J = 7.8 Hz, 1H), 6.88 (bs, 1H), 6.79 (d, J = 7.8 Hz, 1H), 5.24 9s, 2H), 3.62 (t, J = 7.2 Hz, 2H), 2.91 (t, J = 7.2 Hz, 2H); ESI MS m/z 361 $[C_{21}H_{20}N_4O_2 + H]^+$.

Example 110

N-[2-(1H-Imidazol-5-yl)ethyl]-7-hydroxy-1H-indole-3-carboxamide



To a solution of N-(2-(1H-imidazol-5-yl)ethyl)-7-(benzyloxy)-1H-indole-3-carboxamide (0.15 g, 0.42 mmol) in methanol (20 mL) was added 10 wt % Pd on carbon (cat.) and the reaction mixture was stirred under an atmosphere (1 atm) of hydrogen at room temperature for 18 h. The reaction mixture was filtered over diatomaceous earth and the filtrate was concentrated and

purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA). The desired product was obtained as the trifluoroacetic acid salt which was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to afford the desired product (24 mg, 22% yield): ^{1}H NMR (300 MHz, DMSO-d_6) delta 7.92–7.84 (m, 2H), 7.58–7.53 (m, 2H), 6.89–6.82 (m, 2H), 6.54 (d, J = 7.5 Hz, 1H), 3.48–3.42 (m, 2H), 2.74 (t, J = 7.2 Hz, 2H); ESI MS m/z 271 $[C_{14}H_{14}N_4O_2 + H]^+$.

Example 111

Methyl 4-Methoxy-3-(thiophene-2-carboxamido)benzoate



To a solution of methyl 3-amino-4-methoxybenzoate (0.31 g, 1.7 mmol) in CH_2Cl_2 (15 mL) was added EDC (0.48 g, 2.6 mmol), HOBt (0.23 g, 1.7 mmol), and thiophene-2-carboxylic acid (0.27 g, 2.1 mmol) and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated and purified by chromatography (silica gel, 0-70% EtOAc/Heptane) to afford the desired product (0.19 g, 39% yield) as an off-white solid: ESI MS m/z 292 $[C_{14}H_{13}NO_4S + H]^+$.

Example 112

N-{5-[2-(1H-Imidazol-5-yl)ethylcarbamoyl]-2-hydroxyphenyl} thiophene-2-carboxamide



To a solution of methyl 4-methoxy-3-(thiophene-2-carboxamido)benzoate (0.19 g, 0.65 mmol) in dichloroethane (20 mL) was added boron tribromide (6.5 mL, 1.0 M in CH_2Cl_2) and the reaction mixture was heated at 80 degrees for 16 h. The reaction was incomplete by LCMS analysis, therefore, additional boron tribromide (3.3 mL, 1.0 M in CH_2Cl_2) was added and the reaction mixture was heated at 80 degrees for 24 h. The reaction mixture was cooled to room temperature, quenched by the addition of water (15 mL) and the resulting solids were filtered to afford crude hydroxy acid. The crude acid was dissolved in DMF (5 mL) followed by the addition of HATU (0.15 g, 0.46 mmol), DIPEA (0.20 mL, 1.1 mmol), and histamine (0.051 g, 0.46 mmol) and the reaction mixture was heated at 80 degrees for 18 h. The reaction mixture was cooled to room temperature, diluted with water (20 mL), and extracted with EtOAc (3x30 mL). The combined organic layers were dried over Na_2SO_4, concentrated, and the residue was purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA). The desired product was obtained as the trifluoroacetic acid salt which was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to afford the desired

product (36 mg, 27% yield for two steps): ^{1}H NMR (300 MHz, CD_3OD) delta 8.48 (s, 1H), 8.25 (d, J = 3.0 Hz, 1H), 7.86 (d, J = 3.9 Hz, 1H), 7.75–7.73 (m, 1H), 7.52 (dd, J = 8.4, 2.1 Hz, 1H), 7.23–7.18 (m, 2H), 6.95 (d, J = 8.4 Hz, 1H), 3.65 (t, J = 6.9 Hz, 2H), 2.98 (t, J = 6.9 Hz); ESI MS m/z 357 $[C_{17}H_{16}N_4O_3S + H]^+$; HPLC 96.3% (AUC), t_R = 9.15 min.

General Procedure D - synthesis of amines: To a solution of tert-butyl 2-aminoethylcarbamate (1.0 equiv) in dichloromethane (10 mL) was added triethylamine (3.0 equiv) and the requisite sulfonyl chloride or acid chloride (1.2 equiv) and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was concentrated to afford the crude intermediate were dissolved in ethyl acetate (40 mL) followed by the addition of 2 N HCl in diethyl ether (2.85 equiv). The reaction mixture was stirred for 16 h at room temperature. The resulting solids were collected by filtration to afford the desired products. These amines were used in subsequent reactions without further purification.

Example 113
N-(2-Aminoethyl)benzenesulfonamide Trifluoroacetic Acid Salt



•TFA

Following General Procedure D, *tert*-butyl 2-aminoethylcarbamate (0.50 g, 2.8 mmol) was reacted with benzenesulfonylchloride (0.54 g, 3.4 mmol) to afford the intermediate (ESI MS *m/z* 201 $[C_{13}H_{20}N_2O_4S - Boc + H]^+$) which was treated with 2 N HCl. The reaction did not go to completion by LCMS analysis and was concentrated, dissolved in trifluoroacetic acid (5 mL) and stirred for 4 h at room temperature. The reaction mixture was concentrated under reduced pressure to afford the desired product (1.2 g, 99% yield) as a tan solid: ^{1}H NMR (500 MHz, DMSO-d_6) delta 7.90 (t, J = 5.9 Hz, 1H), 7.83–7.81 (m, 4H), 7.69–7.63 (m, 3H), 2.94 (d, J = 6.2 Hz, 2H), 2.86 (d, J = 5.6 Hz, 2H).

Example 114
N-(2-Aminoethyl)-4-chlorobenzenesulfonamide Hydrochloride



•HCl

Following General Procedure D, *tert*-butyl 2-aminoethylcarbamate (0.50 g, 2.8 mmol) was reacted with 4-chlorobenzenesulfonylchloride (0.72 g, 3.4 mmol) to afford the intermediate (ESI MS m/z 235 $[C_{13}H_{19}ClN_2O_4S - Boc + H]^+$) which was treated with 2 N HCl to afford the desired product (0.60 g, 79% yield) as a white solid: ESI MS m/z 235 $[C_8H_{11}ClN_2O_2S + H]^+$.

Example 115
N-(2-Aminoethyl)pyridine-4-sulfonamide Dihydrochloride



Following General Procedure D, *tert*-butyl 2-aminoethylcarbamate (0.54 g, 2.8 mmol) was reacted with 4-pyridylsulfonylchloride (0.73 g, 3.4 mmol) to afford the intermediate which was reacted with 2 N HCl to afford the desired product (0.72 g, 94% yield) as a white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 9.19 (d, J = 2.0 Hz, 1H), 8.97 (dd, J = 5.3, 1.4 Hz, 1H), 8.66–8.64 (m, 1H), 7.99 (dd, J = 8.2, 5.3 Hz, 1H), 3.24–3.19 (m, 2H), 3.11–3.09 (m, 2H).

Examples 116

N-(2-aminoethyl)benzamide Hydrochloride



Following General Procedure D, *tert*-butyl 2-aminoethylcarbamate (0.50 g, 2.8 mmol) was reacted with 4-tolylbenzoylchloride (0.47 g, 3.4 mmol) to afford the intermediate (ESI MS m/z 179 $[C_{15}H_{22}N_2O_3 - Boc + H]^+$) which was reacted with 2 N HCl to afford the desired product (0.40 g, 67% yield) as a white solid: ^{1}H NMR (500 MHz, CD_3OD) delta 7.86 (t, J = 8.5 Hz, 2H), 7.56–7.55 (m, 1H), 7.48 (t, J = 7.5 Hz, 2H), 3.67 (t, J = 5.5 Hz, 2H), 3.17 (t, J = 6.0 Hz, 2H).

Example 117

tert-Butyl 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-ylcarbamate



A solution 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid (0.60 g, 2.2 mmol), $(PhO)_2P(O)N_3$ (0.78 g, 3.0 mmol) and triethylamine (0.70 mL, 5.0 mmol) in 1,4-dioxane (35 mL) were stirred for 4 h at room temperature. Following the addition of *t*–BuOH (2 mL) the reaction mixture was stirred at 100 degrees for 16 h. The reaction mixture was cooled, concentrated, and the residue was purified by column chromatography (silica gel, methanol/methylene chloride gradient) to afford the desired product (360 mg, 47% yield) as a yellow solid: ESI MS *m/z* 346 $[C_{17}H_{19}N_3O_3S + H]^+$.

Example 118

7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-amine Hydrochloride



To a solution of tert-Butyl 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-ylcarbamate (0.44 g, 1.2 mmol) in CH_2Cl_2 (5 mL) was added a 2.0 M HCl in diethyl ether (3.5 mL) and the reaction mixture was stirred at room temperature for 5 h. The resulting precipitate was filtered and washed with CH_2Cl_2 (2x10 mL) to afford the desired product (290 mg, 855 yield) as a white solid: ESI MS *m/z* 246 $[C_{12}H_{11}N_3OS + H]^+$.

Example 119
(E)-3-(1H-imidazol-5-yl)-N-(7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-yl)acrylamide



A solution of (E)-3-(1H-imidazol-5-yl)acrylic acid (0.13 g, 0.94 mmol) and HATU (0.36 g, 1.1 mmol) in THF (4 mL) was stirred at room temperature for 30 min. A solution of 7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-amine hydrochloride (0.18 g, 0.63 mmol) and DIPEA (0.33 mL, 1.9 mmol) in THF (4 mL) was added and the reaction mixture was heated at 60 degrees for 64 h. The reaction mixture cooled, diluted with water (50 mL), and extracted with EtOAc (2x30 mL). The combined organic layers were washed with brine (2x50 mL), dried over sodium sulfate, and concentrated. The residue was purified by column chromatography (silica gel, methanol/methylene chloride gradient) to afford the desired product (200 mg, 87% yield) as an off-white solid: ESI MS *m/z* 366 $[C_{18}H_{15}N_5O_2S + H]^+$.

Example 120
(E)-3-(1H-imidazol-5-yl)-N-(7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-yl) acrylamide



A solution of (E)-3-(1H-imidazol-5-yl)-N-(7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-yl)acrylamide (0.20 g, 0.55 mmol) in CH_2Cl_2 (12 mL) was cooled to 0 degree and BBr_3 (1.6 g, 6.5 mmol) was added dropwise and the reaction mixture was warmed to room temperature and stirred for 16 h. The reaction mixture was concentrated, the residue was stirred in methanol (5 mL) and purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA). The desired fractions were concentrated and eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to obtain the desired product (25 mg, 13% yield) as an off-white solid: ^{1}H NMR (500 MHz, CD_3OD) 7.81 (d, J = 4.5 Hz, 1H) 7.78 (s, 1H), 7.6 (d, J = 8.5 Hz, 1H), 7.59 (s, 1H), 7.51 (d, J = 8.5 Hz, 1H), 7.4 (s, 1H), 7.18, (t, J = 4.25 Hz, 1H), 6.78 (d, J = 15.5, 1H), 6.58 (d, J = 8.5 Hz, 1H); ESI MS *m/z* 352 $[C_{17}H_{13}N_5O_2S + H]^+$.

Example 121

N-(7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-yl)-3-(1H-imidazol-5-yl)propanamide



A solution of (E)-3-(1H-imidazol-5-yl)-N-(7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-yl) acrylamide (19 mg, 0.054 mmol) and 10 wt % Palladium upon carbon (50 mg) in ethanol (20 mL) was placed in a parr shaker with hydrogen gas (50 psi) for 2 h. The reaction mixture was transferred into a round bottom flask, placed under an atmosphere of hydrogen gas (1 atm), and stirred for 16 h. The reaction mixture was filtered through diatomaceous earth, the filtrate was concentrated, and the residue was suspended in CH_2Cl_2 (10 mL). The resulting precipitate was filtered and dried to afford the desired product (12 mg, 63% yield) as a green solid: ^{1}H NMR (500 MHz, CD_3OD); 8.16 (s, 1H), 7.82, (d, J = 4.0 Hz, 1H), 7.38 (d, J = 5.5 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.19 (t, J = 4.2 Hz, 1H), 7.13 (s, 1H), 6.58 (d, J = 8.5 Hz, 1H), 3.09 (t, J = 7.3 Hz, 2H), 2.83 (t, J = 7.5 Hz, 2H); ESI MS *m/z* 354 $[C_{17}H_{15}N_5O_2S + H]^+$.

Example 122

STEP 1: Synthesis of *tert*-butyl 3-(4-methoxy-2-nitrobenzamido)piperidine-1-carboxylate



To a solution of 4-methoxy-2-nitrobenzoic acid (200 mg, 1.0 mmol) and *tert*-butyl 3-aminopiperidine-1-carboxylate (200 mg, 1.0 mmol) in DMF (2 mL) was added DIPEA (0.20 mL, 1.2 mmol) and HATU (460 mg, 1.2 mmol). The reaction mixture was stirred at room temperature for 18 h, diluted with water (10 mL) and ethyl acetate (30 mL), and the layers were separated. The organic phase was washed with water (20 mL), brine (20 mL), dried over Mg_2SO_4, and purified by flash chromatography (silica gel, ethyl acetate/hexanes gradient) to provide the desired product (330 mg, 88%) as a white solid: ESI MS *m/z* 402 $[C_{18}H_{25}N_3O_6 + Na]^+$.

STEP 2: Synthesis of *tert*-butyl 3-(2-amino-4-methoxybenzamido)piperidine-1-carboxylate



To a solution of *tert*-butyl 3-(4-methoxy-2-nitrobenzamido)piperidine-1-carboxylate (190 mg, 0.50 mmol) in EtOH/EtOAc (5 mL each) was added 10 wt % palladium upon carbon (20 mg) and the reaction mixture was stirred under an atmosphere of hydrogen for 3 h. The reaction

mixture was filtered through diatomaceous earth and the filtrate was concentrated to afford the desired product (170 mg, quant.) as a white solid: ESI MS *m/z* 351 $[C_{18}H_{27}N_3O_4 + H]^+$.

STEP 3: Synthesis of *tert*-butyl 3-(4-methoxy-2-(thiophene-2-carboxamido)benzamido) piperidine-1-carboxylate



To a solution of *tert*-butyl 3-(2-amino-4-methoxybenzamido)piperidine-1-carboxylate (170 mg, 0.50 mmol) and DIPEA (120 mg, 1.0 mmol) in CH_2Cl_2 (5 mL) and pyridine (1 mL) at 0 degree was added thiophene-2-carbonyl chloride (88 mg, 0.60 mmol) dropwise. The reaction mixture was stirred for 18 h, concentrated, purified by flash chromatography (silica gel, ethyl acetate/hexanes gradient) to afford the desired product (200 mg, 89%) as a white solid: ESI MS *m/z* 460 $[C_{23}H_{29}N_3O_5S + H]^+$.

STEP 4: Synthesis of *N*-(5-hydroxy-2-(piperidin-3-ylcarbamoyl)phenyl)thiophene-2-carboxamide



To a solution of *tert*-butyl 3-(4-methoxy-2-(thiophene-2-carboxamido) benzamido) piperidine-1-carboxylate (91 mg, 0.20 mmol) in CH_2Cl_2 (3 mL) at -78 degrees was added BBr_3 (2.0 mL, 1.2 mmol, 1 M in CH_2Cl_2) and the reaction mixture was warmed to room temperature and stirred for 18 h. The reaction mixture was quenched by the addition of ice and methanol (2 mL) and concentrated. The residue was purified by preparative HPLC (C18 silica, 10-90% acetonitrile/water with 0.05% TFA). The desired product was obtained as the trifluoroacetic acid salt which was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to afford the desired product (12 mg, 94%) as a white solid: ^{1}H NMR (500 MHz, DMSO-d_6) delta 12.93 (s, 1H), 10.28 (s, 1H), 8.57 (d, J = 12.5 Hz, 1H), 8.09 (d, J = 3.5 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.82 (d, J = 15.0 Hz, 1H), 7.70 (d, J = 4.5 Hz, 1H), 7.28 – 7.25 (m, 1H), 6.58 – 6.55 (m, 1H), 4.19 (s, 1H), 3.57 – 3.55 (m, 1H), 3.46 – 3.33 (m, 2H), 1.91 – 1.87 (m, 2H), 1.68 – 1.30 (m, 5H); ESI MS *m/z* 346 $[C_{17}H_{19}N_3O_3S + H]^+$; HPLC > 99% (AUC), t_R = 9.16 min.

Examples 123
Kinase assay

GSK3beta activity was measured in the presence or absence of compounds using Z'-LYTE kinase assay (Rodems SM, et al., *Assay Drug Dev Technol.* 1: 9-19, 2002.) kit with SER/THR 9 peptide (Invitrogen) following the manufacturer's instruction. The Z'-LYTE kinase assay kit

employs a fluorescence resonance energy transfer (FRET) between two fluorophores, coumarin and fluorescein, attached to each end of a substrate peptide.

Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.04 ng/mcl GSKbeta (Invitrogen) and 2 mcM SER/THR 9 peptide were reacted in a reaction buffer (50 mM HEPES pH 7.5, 0.01% Brij-35, 10 mM $MgCl_2$, 1 mM EGTA, 15 mcM ATP). For 0% phosphorylation control, ATP was omitted from the reaction mixture. For 100% phosphorylation control, SER/THR 9 phosphopeptide was used in place of the SER/THR 9 peptide. Following 1 hour incubation at room temperature, the reaction was stopped by the addition of half assay volume of development solution and further incubated for 1 hour at room temperature. After adding the half assay volume of stop reagent, emission signals of coumarin and fluorescein were measured by Wallac EnVision 2103 multilabel reader (PerkinElmer). The extent of phosphorylation was determined according to the 0% and 100% phosphorylation control samples using the following equation:

$$\%\ \text{phosphorylation} = 1 - \frac{(\text{emission ratio} \times F_{100\%}) - C_{100\%}}{(C_{0\%} - C_{100\%}) + [\text{emission ratio} \times (F_{100\%} - F_{0\%})]}$$

where:

$$\text{emission ratio} = \frac{\text{coumarin emission signal (445nm)}}{\text{fluorescein emission signal (520nm)}}$$

$C_{100\%}$ = coumarin emission signal of the 100% phosphorylation control

$C_{0\%}$ = coumarin emission signal of the 0% phosphorylation control

$F_{100\%}$ = fluorescein emission signal of the 100% phosphorylation control

$F_{0\%}$ = fluorescein emission signal of the 0% phosphorylation control

IC_{50} values were calculated by nonlinear four parameter fit using SigmaPlot, version 10.0 (Systat Software, Inc.).

IC_{50} values of the typical compounds of the present invention are shown in following table 12:

Table 12

Example No.	compound	IC50 (micro M)
76	N-[3-(1H-Imidazol-1-yl)propyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.0017
80	N-(3,4-Dihydroxyphenethyl)-2-(furan-2-yl)-7-hydroxy-1H-benzo[d]imidazole-4-carboxamide	0.019
69	7-Hydroxy-N-{2-[5-(methylsulfonamido)pyridin-2-ylamino]ethyl}-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.022
15	Methyl 3-Hydroxy-2-[7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]propanoate	0.022
79	7-Hydroxy-N-[3-(5-oxo-4,5-dihydro-1H-pyrazol-4-yl)propyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.03

37	N-(3,4-Dihydroxybenzyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.038
8	7-Hydroxy-N-(4-sulfamoylbenzyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.052
49	N-[2-(5-Carbamoylpyridin-2-yloxy)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.073
42	N-(2-Acetamidoethyl)-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.074
70	N-[2-(5-Acetamidopyridin-2-ylamino)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.081
101	2-Cyclopropyl-4-hydroxy-N-(4-sulfamoylphenethyl)-1H-benzo[d]imidazole-7-carboxamide	0.12
35	7-Hydroxy-N-[2-(1-methyl-1H-imidazol-5-yl)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.13
11	7-Hydroxy-N-[2-(pyridin-2-ylamino)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.13
97	2-Cyclopropyl-N-(2,3-dihydroxypropyl)-4-hydroxy-1H-benzo[d]imidazole-7-carboxamide	0.15
17	(R)-7-Hydroxy-N-[1-hydroxy-3-(1H-imidazol-4-yl)propan-2-yl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.17
12	7-Hydroxy-N-[3-(2-hydroxyethylamino)propyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.18
36	N-[2-(dimethylamino)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.18
43	N-[3-(Isopropylamino)propyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.22
62	N-[2-(1H-Imidazol-2-yl)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.26
21	7-Hydroxy-N-(4-sulfamoylphenethyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.28
71	(S)-2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(1H-imidazol-5-yl)propanoic Acid	0.34
40	7-Hydroxy-N-[2-(pyridine-4-sulfonamido)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide	0.39

93	N-(4-Aminophenethyl)-4-hydroxy-2-phenyl-1H-benzo[d]imidazole-7-carboxamide	0.4
91	2-Cyclopropyl-N-(4-hydroxyphenyl)-4-methoxy-1H-benzo[d]imidazole-7-carboxamide	0.4
120	(E)-3-(1H-imidazol-5-yl)-N-(7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-yl) acrylamide	3
121	N-(7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-yl)-3-(1H-imidazol-5-yl)propanamide	1.7
122	*N*-(5-hydroxy-2-(piperidin-3-ylcarbamoyl)phenyl)thiophene-2-carboxamide	8.1

Industrial Applicability

The present invention provides a novel benzoimidazole compound having GSK3beta inhibitory effect. The compounds of the present invention may be used for pharmaceutical composition for inhibiting GSK3-beta. Such pharmaceutical compositions are suitable for treating or preventing diseases involving GSK3beta.

Claims

1. A compound represented by formula (I), or a salt, hydrate, solvate, or isomer thereof:



(I)

wherein

Ring A is represented by the formula:



(II) (III) (IV) (V) or (VI)

wherein

X is halogen or hydroxyl;

Y is hydrogen, phenyl, thiophen-2-yl, furan-2-yl, cyclopropyl, or cyclopentyl;

Z is a 5-10 membered heterocycle substituted carbonylamino; and

$-L^1-(CH_2)_a-L^2-M$ is at position *;

wherein, L^1 is -CONH-, -NHCO-, or a single bond;

L^2 is selected from the group consisting of -NH-, -O-, $-CH(COOR^1)-$, $-CH(CH_2OH)-$, -CH=CH- and a single bond, and wherein R^1 is hydrogen or C_1-C_6 alkyl; and

M is selected from the group consisting of hydroxyl, carboxyl, amide, C_1-C_6 alkyl, C_1-C_6 alkylcarbonyl, C_6-C_{14} aryl, C_6-C_{14} aryl C_1-C_6 alkyl, C_6-C_{14} arylcarbonyl, C_6-C_{14} arylsulfonyl, a 5-14 membered saturated, unsaturated or aromatic heterocyclic group, a 5-14 membered unsaturated or aromatic heterocyclic group substituted C_1-C_6 alkyl, a 5-14 membered unsaturated or aromatic heterocyclic group substituted sulfonyl, and $-NR^2R^3$, wherein R^2 and R^3 are each independently C_1-C_6 alkyl;

wherein the C_1-C_6 alkyl, the C_1-C_6 alkylcarbonyl, the C_6-C_{14} aryl, the C_6-C_{14} aryl C_1-C_6 alkyl, the C_6-C_{14} arylcarbonyl, the C_6-C_{14} arylsulfonyl, the 5-14 membered unsaturated or aromatic heterocyclic group, the 5-14 membered unsaturated or aromatic heterocyclic group substituted C_1-C_6 alkyl, or the 5-14 membered unsaturated or aromatic heterocyclic group substituted sulfonyl is optionally substituted by 1-3 substituent(s), each independently selected from group A;

wherein group A is selected from the group consisting of hydroxyl, oxo, nitro, amino, amide, halogen, sulfamoyl, trifluoromethyl, p-toluenesulfonylamino, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkylcarbonylamino, and C_1-C_6 alkylsulfonylamino; and a is an integer from 0-5.

2. The compound of Claim 1, which is represented by formula (I-II):



(I-II)

wherein

L^1 is -CONH-;

L^2 is a single bond; and

M is C_6-C_{10} aryl or a 5-10 membered unsaturated or aromatic heterocycle group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S, each of which is optionally substituted by 1 or 2 substituent(s) each independently selected from the group A.

3. The compound of Claim 2, wherein M is phenyl, imidazole-1-yl, imdazole-2-yl, imidazole-5-yl, thiophen-2-yl, pyrole-2-yl, 1,3-thiazole-2-yl, 2-pyrazoline-4-yl, or isoxazole-4-yl, each of which is optionally substituted by 1-2 substituent(s) each independently selected from group B;

wherein group B is selected from the group consisting of fluoro, hydroxyl, oxo, amino, methyl, methoxy, and sulfamoyl.

4. The compound of Claim 1, which is represented by formula (I-II):



(I-II)

wherein

L^1 is -CONH-;

L^2 is -NH-; and

M is C_1-C_4 alkyl, C_1-C_4 alkylcarbonyl, C_6-C_{10} arylcarbonyl, C_6-C_{10} arylsulfonyl, a 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S or sulfonyl substituted by a 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S, each of which is optionally substituted by 1 or 2 substituent(s) each independently selected form the group A.

5. The compound of Claim 4, wherein M is ethyl, isopropyl, methylcarbonyl, pyridine-2-yl, phenylcarbonyl, phenylsulfonyl, or 4-pyridylsulfonyl, each of which is optionally substituted by 1-2 substituent(s) each independently selected from group C;

wherein group C is selected from the group consisting of chloro, hydroxyl, methyl, methylcarbonylamino, methylsulfonylamino, and p-toluenesulfonylamino.

6. The compound of Claim 1, which is represented by formula (I-II):



(I-II)

wherein

L^1 is -CONH-;

L^2 is -CH(COOR^1)-, wherein R^1 is hydrogen or C_1-C_4 alkyl; and

M is C_1-C_4 alkyl, C_6-C_{10} aryl C_1-C_4 alkyl or C_1-C_4 alkyl substituted by a 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S, each of which is optionally substituted by 1 or 2 substituent(s) each independently selected from the group A.

7. The compound of Claim 6, wherein M is methyl, phenylmethyl, indole-3-ylmethyl, or imidazole-4-ylmethyl, each of which is optionally substituted by 1-2 hydroxyl group(s).

8. The compound of Claim 1, which is represented by formula (I-II):



(I-II)

wherein

L^1 is -CONH-;

L^2 is - O-; and

M is C_6-C_{10} aryl or a 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S, each of which is optionally substituted by 1 or 2 substituent(s) each independently selected from the group A.

9. The compound of Claim 8, wherein M is phenyl or pyridine-2-yl, each of which is optionally substituted by 1 or 2 substituent(s) each independently selected from group D;

wherein group D is selected from the group consisting of amide, nitro, trifluoromethyl, and p-toluenesulfonylamino.

10. The compound of Claim 1, which is represented by formula (I- II):



(I-II)

wherein

L^1 is -CONH-;

L^2 is - $CH(CH_2OH)$-; and

M is selected from the group consisting of hydroxyl, C_1-C_4 alkyl, C_6-C_{10} aryl C_1-C_4 alkyl, and C_1-C_4 alkyl substituted by a 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S,

wherein the C_1-C_4 alkyl, C_6-C_{10} aryl C_1-C_4 alkyl, and 5-10 membered unsaturated or aromatic heterocyclic group, are each optionally substituted by 1 or 2 substituent(s) each independently selected from the group A.

11. The compound of Claim 10, wherein M is hydroxyl, phenylmethyl, *t*-butyl, or imidazole-5-ylmethyl.

12. The compound of Claim 1, which is represented by formula (I- II):



(I-II)

wherein

L^1 is -CONH-;

L^2 is a single bond; and

M is $-NR^2R^3$;

wherein R^2 and R^3 are each independently C_1-C_4 alkyl optionally substituted by 1 or 2 substituent(s) each independently selected from the group A.

13. The compound of Claim 1, which is represented by formula (I- II):



(I-II)

wherein

L^1 is -NHCO-;

L^2 is -NH-, -CH=CH- or a single bond; and

M is C_6-C_{10} aryl or a 5-10 membered unsaturated or aromatic heterocyclic group having 1-2 hetero atom(s) selected from the group consisting of N, O, and S, each of which is optionally substituted by 1 or 2 substituent(s) each independently selected from the group A.

14. The compound of Claim 13, wherein M is phenyl optionally having 1 or 2 hydroxyl or imidazol-5-yl group(s).

15. The compound of Claim 1, which is represented by formula (I-III):



(I-III)

wherein
L^1 is -CONH- or a single bond;
L^2 is a single bond; and
M is amide or a 5-10 membered unsaturated or aromatic heterocyclic group having 1 or 2 hetero atom(s) selected from the group consisting of N, O, and S, optionally substituted by 1 or 2 substituent(s) each independently selected from the group A.

16. The compound of Claim 1, which is represented by formula (I-IV):



(I-IV)

wherein
L^1 is -CONH-;
L^2 is a single bond; and
M is a 5-10 membered unsaturated or aromatic heterocyclic group having 1 or 2 hetero atom(s) selected from the group consisting of N, O, and S, optionally substituted by 1 or 2 substituent(s) each independently selected from the group A.

17. The compound of Claim 1, which is represented by formula (I-V) or (I-VI):



(I-V)



(I-VI)

wherein
L^1 is -CONH-;
L^2 is a single bond; and
M is a 5-10 membered saturated, unsaturated or aromatic heterocyclic group having 1 or 2 hetero atom(s) selected from the group consisting of N, O, and S, optionally substituted by 1 or 2 substituent(s) each independently selected from the group A.

18. The compound of Claim 1,
wherein
L^1 and L^2 are both a single bond;
M is carboxyl or amide; and
a is 0.

19. The compound of any one of Claims 1-16 and 18,
wherein Y is thiophen-2-yl.

20. The compound of any one of Claims 1-16 and 18, wherein Y is furan-2-yl.

21. The compound of any one of Claims 1-16 and 18, wherein Y is phenyl.

22. The compound of any one of Claims 1-16 and 18, wherein Y is cyclopropyl.

23. The compound of any one of Claims 1-16 and 18, wherein Y is cyclopentyl.

24. The compound of any one of Claims 1-16 and 18, wherein Y is hydrogen.

25. The compound of any one of Claims 1, 17, and 18, wherein Z is thiophen-2-ylcarbonylamino.

26. The compound of Claim 1, which is selected from the group consisting of:
7-Hydroxy-*N*-[2-(phenylsulfonamido)ethyl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
N-[2-(4-Chlorophenylsulfonamido)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
N-[2-(5-Carbamoylpyridin-2-yloxy)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
N-(2,4-Difluorobenzyl)-7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-(4-sulfamoylbenzyl)-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-(3-methoxyphenethyl)-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
N-[2-(5-Acetamidopyridin-2-ylamino)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide,
N-[3-(1*H*-Imidazol-1-yl)propyl]-7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-(4-sulfamoylphenethyl)-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-{2-[5-(methylsulfonamido)pyridin-2-ylamino]ethyl}-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-[2-(1-methyl-1*H*-imidazol-5-yl)ethyl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-N-[2-(4-nitrophenoxy)ethyl]-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide,
Methyl
3-Hydroxy-2-[7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamido]propanoate,
N-[2-(dimethylamino)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
(S)-2-[7-Hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamido]-3-(1H-indol-3-yl)propanoic Acid,
7-Hydroxy-2-(thiophen-2-yl)-*N*-[2-(thiophen-2-yl)ethyl]-1*H*-benzo[*d*]imidazole-4-carboxamide,
N-(2-Acetamidoethyl)-7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
N-3-(1*H*-Imidazol-2-yl)propyl)-]7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,

Methyl 2-[7-Hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamido]-3-(4-hydroxyphenyl)propanoate,
N-[2-(1*H*-Imidazol-2-yl)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
2-(Furan-2-yl)-7-hydroxy-*N*-phenethyl-1*H*-benzo[*d*]imidazole-4-carboxamide,
2-(Furan-2-yl)-7-hydroxy-*N*-phenyl-1*H*-benzo[*d*]imidazole-4-carboxamide,
2-(Furan-2-yl)-7-hydroxy-*N*-[2-(1-methyl-1*H*-pyrrol-2-yl)ethyl]-1*H*-benzo[*d*]imidazole-4-carboxamide,
2-(Furan-2-yl)-7-hydroxy-*N*-(thiazol-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-[3-(5-oxo-4,5-dihydro-1*H*-pyrazol-4-yl)propyl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
N-(2-(3,5-dimethylisoxazol-4-yl)ethyl)-2-(furan-2-yl)-7-hydroxy-1*H*-benzo[*d*]imidazole-4-carboxamide,
1-(2-Cyclopropyl-7-hydroxy-1*H*-benzo[*d*]imidazol-4-yl)-3-(4-hydroxyphenyl)urea,
N-(2-cyclopropyl-7-hydroxy-1*H*-benzo[*d*]imidazol-4-yl)-2-(4-hydroxyphenyl)acetamide,
2-Cyclopentyl-4-hydroxy-*N*-(4-hydroxyphenethyl)-1*H*-benzo[*d*]imidazole-7-carboxamide,
N-(4-Aminophenethyl)-2-cyclopentyl-4-hydroxy-1*H*-benzo[*d*]imidazole-7-carboxamide,
4-Hydroxy-*N*-(4-hydroxyphenethyl)-2-phenyl-1*H*-benzo[*d*]imidazole-7-carboxamide,
N-(4-Aminophenethyl)-4-hydroxy-2-phenyl-1*H*-benzo[*d*]imidazole-7-carboxamide,
4-Hydroxy-*N*-phenethyl-2-phenyl-1*H*-benzo[*d*]imidazole-7-carboxamide ,
7-hydroxy-N-(3-methoxyphenethyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-4-carboxamide,
N-(4-Fluorophenethyl)-7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-[2-(pyridine-4-sulfonamido)ethyl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-[2-(4-methylbenzamido)ethyl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-(thiazol-2-yl)-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-2-(thiophen-2-yl)-*N*-[2-(5-(trifluoromethyl)pyridin-2-yloxy)ethyl]-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-[2-(pyridin-2-ylamino)ethyl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-(4-hydroxyphenethyl)-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-*N*-{2-[4-(4-methylphenylsulfonamido)phenoxy]ethyl}-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
(*S*)-2-[7-Hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamido]-3-(1*H*-imidazol-5-yl)propanoic Acid,
(*S*)-Methyl 2-[7-Hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamido]-3-(1*H*-indol-3-yl)propanoate,
(*S*)-Methyl 2-[7-Hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamido]-3-(1*H*-imidazol-5-yl)propanoate,
7-Hydroxy-*N*-[3-(2-hydroxyethylamino)propyl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
N-[3-(Isopropylamino)propyl]-7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
(*S*)-7-Hydroxy-*N*-(1-hydroxy-3-phenylpropan-2-yl)-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
7-Hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxylic acid,

(*S*)-7-Hydroxy-*N*-(1-hydroxy-3,3-dimethylbutan-2-yl)-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
(*R*)-7-Hydroxy-*N*-[1-hydroxy-3-(1*H*-imidazol-4-yl)propan-2-yl]-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
N-(3,4-Dihydroxybenzyl)-7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
2-(Furan-2-yl)-7-hydroxy-*N*-{2-[5-(4-methylphenylsulfonamido)pyridin-2-ylamino]ethyl}-1*H*-benzo[*d*]imidazole-4-carboxamide,
N-(3,4-Dihydroxyphenethyl)-2-(furan-2-yl)-7-hydroxy-1*H*-benzo[*d*]imidazole-4-carboxamide,
2-Cyclopropyl-*N*-(4-hydroxyphenyl)-4-methoxy-1*H*-benzo[*d*]imidazole-7-carboxamide,
2-Cyclopropyl-4-hydroxy-*N*-(4-sulfamoylphenethyl)-1*H*-benzo[*d*]imidazole-7-carboxamide,
2-Cyclopropyl-*N*-(4-fluorophenethyl)-4-hydroxy-1*H*-benzo[*d*]imidazole-7-carboxamide,
2-Cyclopropyl-*N*-(2,3-dihydroxypropyl)-4-hydroxy-1*H*-benzo[*d*]imidazole-7-carboxamide,
2-Cyclopropyl-*N*-(2-(dimethylamino)ethyl)-4-hydroxy-1*H*-benzo[*d*]imidazole-7-carboxamide,
7-Hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-5-carboxamide (Example No. 65),
N-[2-(1*H*-Imidazol-5-yl)ethyl]-7-hydroxy-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-5-carboxamide,
N-{5-[2-(1*H*-Imidazol-5-yl)ethylcarbamoyl]-2-hydroxyphenyl}thiophene-2-carboxamide,
N-[2-(1*H*-Imidazol-5-yl)ethyl]-7-fluoro-2-(thiophen-2-yl)-1*H*-benzo[*d*]imidazole-4-carboxamide,
N-[2-(1*H*-Imidazol-5-yl)ethyl]-7-hydroxy-1*H*-indole-3-carboxamide,

(E)-3-(1H-imidazol-5-yl)-N-(7-methoxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-yl) acrylamide,

N-(7-hydroxy-2-(thiophen-2-yl)-1H-benzo[d]imidazol-4-yl)-3-(1H-imidazol-5-yl)propanamide, and

N-(5-hydroxy-2-(piperidin-3-ylcarbamoyl)phenyl)thiophene-2-carboxamide.

27. A method for preparing a compound of any one of Claims 2-15 which comprises the steps of:
reacting a carboxyalkyl substituted aniline derivative with nitrile in the presence of an acid;
cyclizing the intermediate amidine to obtain a benzimidazole derivative;
saponifying the carboxyalkyl of the benzimidazole derivative; and
forming an amide by either coupling the obtained carboxylic acid with an amine derivative, which may be further modified and extended after coupling, or converting the carboxylic acid to an amine and then coupling with a carboxylic acid derivative, which may be further modified and extended after coupling, to obtain the amide compounds of any one of Claims 2-15.

28. A method for preparing a compound of Claim 16 which comprises the steps of:
treating an indole derivative with trifluoroacetic acid anhydride to obtain a trifluoromethylketone;
hydrolyzing to the carboxylic acid; and
coupling the carboxylic acid with an amine derivative to obtain the compound of Claim 16.

29. A method of preparing a compound of Claim 17 which comprises the steps of:
coupling a carboxyalkyl substituted aniline derivative with a carboxylic acid derivative;
hydrolyzing the carboxymethyl of the obtained amide to obtain a carboxylic acid; and
coupling the carboxylic acid with an amine derivative to obtain the compound of Claim 17.

30. A pharmaceutical composition comprising at least one compound of Claim 1 and a pharmaceutically acceptable carrier.

31. A pharmaceutical composition of Claim 30 which is available for preventing or treating diseases selected from the group consisting of Alzheimer disease, mania, depression, migraine and type 2 diabetes.

32. A glycogen synthase kinase-3 Beta inhibitor comprising at least one compound of Claim 1.

****

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 09/52225

A. CLASSIFICATION OF SUBJECT MATTER
IPC(8) - A01N 43/30 (2009.01)
USPC - 514/466
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
USPC: 514/466
IPC (8): A01N 43/30 (2009.01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC: 514/466 ; 514/596 ;549/436 ; 435/15 ; 564/48 (See keywords below)
IPC (8): A01N 43/30 (2009.01) (See keywords below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WEST: DB=PGPB,USPT,USOC,EPAB,JPAB: Google: Scholar/patents: benzimidazole glycogen synthase kinase-3 beta inhibitors

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---- Y	US 7,179,832 B2 (CHO et al) 20 February 2007 (20.02.2007) Col 1, ln 57-67; Col 2, ln 1-38;Col 7 and Col 8, Scheme I; Col 12, ln 34-41	1-12;21;26;27;30-32 ---------- 13-20;22-25;28-29
Y	US 2007/0270420 A1 (HARBESON et al) 22 November 2007 (22.11.2007) para 0018]-[0021];[0024];[0028]-[0029];[0047]	13;14;16;18-20;22-24;28
Y	US 7,064,215 B2 (RENHOWE et al) 20 June 2006 (20.06.2006) ol 8, ln 20-35; Col 8, ln 39-40; Col 8, ln 51; Col 8, ln 55-56	15
Y	MEIJER et al "Pharmacological inhibitors of glycogen synthase kinase 3" Trends in Pharmacological Sciences, Vol 25, September 2004, pp 471-480. pg 474, Figure 2; pg 475, Figure 3	17;22;24;25;29

☐ Further documents are listed in the continuation of Box C. ☐

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
26 September 2009 (26.09.2009)	08 OCT 2009
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774